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Mission of the Annual Postdoctoral Science Symposium 
To provide a platform for talented postdoctoral fellows throughout the Texas 
Medical Center to present their work to a wider audience, the MD Anderson 
Postdoctoral Association convened the inaugural Annual Postdoctoral Science 
Symposium (APSS) on August 4, 2011. 
 
The APSS provides a professional venue for postdoctoral scientists to develop, 
clarify, and refine their research as a result of formal reviews and critiques by 
faculty and other postdoctoral scientists. Additionally, attendees discuss current 
research on a broad range of subjects while promoting academic interactions 
and enrichment and developing new collaborations. 
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Oral Presentations 
Oral presentations were in the following categories: Applied Science, Basic 
Research, and Clinical/Translational Research. Each category included up to 
four presenters, all of whom were required to be first authors of their submitted 
abstracts. 
 
Please note only abstracts of presenters who agreed to have their abstracts 
published are included. 
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APPLIED SCIENCE 
Poor Oral Hygiene Is Associated with HPV-Negative not HPV-
Positive Oral Cancer  
Jitesh Shewale, PhD1, Robert Pickard2, Maura Gillison, MD, PhD1  
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD 
Anderson Cancer Center, Houston, TX; 2The Ohio State University Comprehensive Cancer 
Center, Columbus, OH 
 
Background: Oral health behaviors have been implicated as risk factors for oral 
squamous cell carcinoma (OSCC; i.e., oral cavity and oropharyngeal cancers), and we 
recently reported that these risk factors also dramatically alter the oral microbiome. As 
described herein, we performed a detailed analysis of associations between oral health 
behaviors and OSCC in a matched case-control study. We stratified our analysis to 
compare and contrast associations with human papillomavirus (HPV)-positive and -
negative OSCC. 
 
Methods: Cases were patients with newly diagnosed OSCC at The Ohio State 
University Comprehensive Cancer Center from 2011 to 2014. Controls were patients 
without cancer at the same outpatient clinic who were individually matched (2:1) with 
each case according to sex, age (5-year intervals), and race (white, black, or other). 
Cases were stratified by tumor high-risk HPV status (HPV-positive, n = 117; HPV-
negative, n = 114) based on E6 or E7 mRNA expression. Data on demographics, 
tobacco and alcohol use, sexual history, and oral health behaviors were collected using 
an audio computer-assisted self-interview. Conditional logistic regression was used to 
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calculate odds ratios (ORs) and 95% confidence intervals (CIs), and oral health 
behaviors significant in univariable analysis (p<0.25) were evaluated using separate 
multivariable models. 
 
Results: In univariable analysis, oral health behaviors such as frequency of dental clinic 
visits, tooth brushing, dental flossing, and gum bleeding; tooth loss; and denture use 
markedly increased the risk of HPV-negative OSCC, whereas none of these behaviors 
increased the risk of HPV-positive OSCC. Also, in univariable analysis, covariates that 
independently increased the risk of HPV-negative OSCC were low income level, high 
lifetime number of cigarette pack-years (never-smoker, >1-<15, ≥15-<30, ≥30-<45, and 
>45), and high lifetime number of alcohol drink-years (never-drinker, <25, ≥25-<100, 
≥100-<200, and ≥200), whereas high lifetime number of marijuana hit-years (<10, ≥10-
<50, and ≥50 ) decreased the risk of HPV-negative OSCC. The covariates that 
independently increased the risk of HPV-positive OSCC were low education level and 
high number of oral sex partners (0-2, 3-6, and ≥7). After adjusting for covariates in 
multivariable analysis, fewer than one dental clinic visit per year independently increased 
the risk of HPV-negative OSCC (OR, 1.98 [95% CI, 1.05-3.75]). Dental flossing less 
often than once per day also independently increased the risk of HPV-negative OSCC 
overall (OR, 2.36 [95% CI, 1.26-4.45]) and in those without dentures (OR, 1.92 [95% CI, 
1.01-3.63]). In multivariable analysis, frequency of tooth brushing and gum bleeding, 
denture use, and tooth loss were not associated with HPV-negative OSCC. 
 
Conclusion: Poor oral health behaviors such as infrequent dental visits and dental 
flossing were independently associated with HPV-negative OSCC but not HPV-positive 
OSCC. These findings are consistent with the hypothesis that poor oral health behaviors 
alter oral microbial composition to promote chronic inflammation and the development of 
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HPV-negative OSCC. Thus, public health efforts in promoting good oral health behaviors 
would have implications for primary prevention of HPV-negative OSCC. 
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3D Breast Treatment Planning Simulation: A Novel, CT-Free 
Approach for Low- and Middle-income Countries 
Yvonne Roed, PhD1, Rex Cardan, PhD2, Simona Shaitelman, MD3, Anuja Jhingran, 
MD3, Daniel Craft, PhD4, Rebecca Howell, PhD1, Richard Popple, PhD2, Laurence Court, 
PhD1 
1Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 
Houston, TX; 2Department of Radiation Oncology, The University of Alabama at Birmingham, 
Birmingham, AL; 3Department of Radiation Oncology, The University of Texas MD Anderson 
Cancer Center, Houston, TX; 4Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ  
 
Objective: Many radiation therapy centers in low- and middle-income countries lack 
reliable access to pretreatment imaging devices such as computed tomography (CT) 
simulators, which are commonly used to generate patient-specific 3D radiation treatment 
plans. In these situations, the dose for each breast cancer patient is calculated to only a 
single point based solely on the separation of the breast. We aimed to develop a low-
cost, CT-free approach to patient-specific 3D breast radiation treatment planning. 
 
Methods: A process to generate simplified, synthetic CT images using three Microsoft 
Kinect cameras was developed. These images are combined into a surface map from 
which orthogonal slices are constructed and converted into simplified, synthetic CT 
images. The CT images only contain information about the outer body shape without any 
internal anatomy. Several camera positions were investigated and optimized to provide 
the most reliable surface map. This system was tested using both anthropomorphic 
breast (n = 2) and chest wall (n = 8) phantoms, including six in-house 3D-printed chest 
wall phantoms (based on actual patient CT images). Distances between landmarks (e.g., 
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separation between the midline and midaxillary line) were measured on synthetic and 
real CT images of these phantoms to assess geometric accuracy. The 3D-printed 
phantoms were then set up on a CT simulator in a supine breast treatment position, and 
real CT images were acquired, followed by acquisition of synthetic CT images. To 
evaluate the agreement between real and synthetic CT images, both image sets were 
imported into a treatment planning system and registered. 
 
Results: The most reliable surface map was achieved when all three cameras were 
positioned on the ipsilateral side of the phantom facing the object at an angle of 30° from 
vertical and stacked with the two outer cameras about 20 cm higher than the middle 
camera. All measured distances on the actual and synthetic CT images differed by fewer 
than 5 mm (average, 1.8 ± 1.3 mm [range, 0.5-4.8 mm]). Eighty percent of all 
measurements were within 2 mm. Both image sets were registered by manually shifting 
the synthetic CT images by less than 6 cm in the inferior direction (average, 4.8 ± 0.62 
cm [range, 4.3-5.5 cm]) and by less than 1 cm to the left (average, 0.9 ± 0.2 cm [range, 
0.7-1.0 cm]). 
 
Conclusion: This camera system could be an inexpensive solution for CT-free 3D 
breast radiation treatment planning. The system can reliably reproduce phantom 
geometry to within a few millimeters between actual and measured phantom geometries. 
Correct representation of the phantom geometry and registration of real and synthetic 
CT images are important first steps in developing a CT-free breast radiation treatment 
planning system for low- and middle-income countries. Further studies of spatial 
agreement metrics between real and synthetic CT images are in progress, as reliable 
agreement is a determining factor in generating clinically acceptable breast radiation 
treatment plans using only synthetic CT images. 
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Mining Big Data to Estimate the Frailty Index in Patients with 
Congestive Heart Failure: Clinical Expert vs. Machine Learning 
Javad Razjouyan, PhD1,5,7, Aanand D. Naik, MD1,2,4,5,7, Bijan Najafi, PhD6, Jacquelene 
Shahin, MS1,2,5, Salim S Virani, MD1,3, Molly J Horstman, MD1,2,5 
1VA HSR&D, Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA 
Medical Center, Houston, TX; 2Section of Health Services Research, Department of Medicine, 
3Section of Cardiovascular Research, 4Section of Geriatrics, Department of Medicine, Baylor 
College of Medicine, Houston, TX; 5VA Quality Scholars Coordinating Center, IQuESt, Michael E. 
DeBakey VA Medical Center, Houston, TX; 6Interdisciplinary Consortium on Advanced Motion 
Performance (iCAMP), Division of Vascular Surgery and Endovascular Therapy, Michael E. 
DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX; 7Big Data Scientist 
Training Enhancement Program (BD-STEP), VA Office of Research and Development, 
Washington, DC 
 
Introduction: Early recognition of frailty in older adults with congestive heart failure 
(CHF) is needed to target interventions to slow functional decline and improve patient-
centered outcomes. Previous studies used laboratory values and vital signs to measure 
a frailty index (FI) to predict mortality. However, variable selection was based on expert 
opinion alone. 
 
Hypothesis: We hypothesize that an FI for CHF patients developed by mining 
laboratory values and vital signs with a machine learning algorithm will better predict 
mortality than will an FI developed based on expert opinion. 
 
Methods: This was a retrospective cohort study of patients with hospital admissions for 
CHF in the Veterans Health Administration from 2012 to 2014. Results of outpatient 
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laboratory tests and vital sign measurements for which more than 50% of the cohort had 
reported values were collected for the year prior to admission. Two physicians reviewed 
the laboratory test results and vital signs and used expert opinion to determine which 
variables may be associated with physical frailty. The laboratory tests and vital signs 
were also fed into a machine learning algorithm to select variables. The accumulation of 
deficits method was used to calculate the FI. Cox survival models were developed with 
the machine learning variables, expert opinion variables, and a combination of the two. 
The outcome of interest was mortality. The performance of the models was compared 
using time-dependent area under the curve with 10-fold cross-validation. 
 
Results: The cohort consisted of 24,457 patients (age, 72 ± 11 years; 98% male) with a 
70% mortality rate in 6 years. Of 53 variables (49 laboratory test results and 4 vital 
signs), the physicians selected 29 variables, the machine selected 23, and the 
physicians and machine agreed on 14. The average area under the curve was 0.561 
(95% confidence interval [CI], 0.561-0.562) for the expert opinion FI, 0.605 (95% CI, 
0.604-0.606) for the machine FI, and 0.607 (95% CI, 0.606-0.608) for the combination 
FI. 
 
Conclusions: The FI developed using the machine learning algorithm was a better 
predictor of mortality than was the FI developed based on expert opinion and used fewer 
variables. This study showed the potential for operationalizing an FI using laboratory 
values and vital signs from electronic health records. In future studies, we plan to feed 
additional clinical variables into the machine learning algorithm to improve the accuracy 
of the FI model. 
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BASIC RESEARCH 
Generation of Bona Fide Prions by Large-Scale Protein 
Misfolding Cyclic Amplification  
Fei Wang, PhD, Luis Concha-Marambio, PhD, Enrique Armijo, PhD, Claudio Soto, PhD 
Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, 
McGovern Medical School at The University of Texas Health Science Center at Houston, 
Houston, TX 
 
Misfolding of the normal prion protein PrPC into the pathogenic prion protein PrPSc is the 
key event causing prion diseases. However, the molecular mechanism underlying this 
conformational conversion remains elusive, largely due to the absence of high-resolution 
structural information on PrPSc, impeding the development of efficacious therapeutic 
strategies for these currently incurable diseases. We present herein our latest results of 
large-scale production of bona fide prions using protein misfolding cyclic amplification 
(PMCA) to facilitate structural studies of PrPSc, which not only provides a platform for 
ultrasensitive detection of prions in biological samples but also can faithfully reproduce 
the key properties of prions, including infectivity, species barriers, and strain variability. 
In a pilot study, normal mouse brain homogenates were seeded with RML prion in large 
containers to produce bona fide prions using PMCA in reaction volumes ranging from 30 
to 120 mL. The prion yielded in this large-scale production maintained the RML prion 
strain characteristics in terms of infectivity in wild-type animals, incubation time, PrPSc 
biochemical profile, and pathological changes. In a follow-up study, a recombinant prion 
generated from bacterially expressed full-length recombinant mouse prion protein 
seeded with the RML prion was used to seed the large-scale production of recombinant 
PrPSc using PMCA. This large-scale PMCA (LS-PMCA) platform is capable of producing 
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at least 2 mg of PK-resistant recombinant PrPSc in a 200-mL reaction in 24 hours and 
can scale up to 1,000 mL per round of LS-PMCA. An infectivity assessment of the 
recombinant PrPSc from LS-PMCA is ongoing. Availability of a procedure to produce 
massive amounts of PrPSc using a recombinant protein as a substrate, which maintains 
the typical biological and biochemical properties of bona fide prions, will facilitate 
structural and biochemical studies of infectious prions. 
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Spatial Nucleus Barcoding Integrates Cellular Genomics and 
Tissue Architecture in Normal and Malignant Breast Tissues 
Kaile Wang, PhD1, Min Hu, MS1, Shanshan Bai, MS1,2, Mashiat Rabbani, MS3, Hui 
Chen, MD, PhD4, Bora Lim, MD5, Nicholas E. Navin, PhD1,6,7 
1Department of Genetics, 2Department of Genitourinary Medical Oncology, 3School of Health 
Professions, 4Department of Pathology, 5Department of Breast Medical Oncology, The University 
of Texas MD Anderson Cancer Center, Houston, TX; 6MD Anderson Cancer Center UTHealth 
Graduate School of Biomedical Sciences, Houston, TX; 7 Department of Bioinformatics and 
Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX  
 
The expression programs of cell types in tissues and their spatial organization are critical 
for understanding homeostatic functions of normal tissues and the progression of 
diseases such as cancer. However, current single-cell RNA-sequencing methods 
inherently lose all spatial information on cellular localization. To overcome this technical 
obstacle, we developed a spatial nucleus barcoding (SNUBAR) technology that delivers 
spatial barcodes into tissue regions, after which barcoded nuclei are used for high-
throughput single-nucleus RNA sequencing. We validated this method in sample 
barcoding and intermixing experiments with cell lines, which showed high efficiency of 
barcode delivery and doublet identification. We applied SNUBAR to 36 spatial regions of 
a normal breast tissue, which identified nine major cell types and three distinct spatial 
regions (fatty, fibroblast, and epithelial). The fatty region was mainly composed of 
adipocytes that co-localized with a distinct lipo-fibroblast expression state, whereas the 
fibroblast region contained matrix-producing fibroblasts that co-localized with 
proangiogenic macrophages and vascular endothelial cells. The epithelial areas were 
composed of three distinct epithelial cell types that co-localized with lymphatic 
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endothelial cells and another fibroblast expression program. We further applied 
SNUBAR to 15 spatial regions of an invasive breast tumor, which identified four cell 
types in the microenvironment in addition to the tumor cells. Whereas most immune and 
stromal cells were uniformly distributed across the 15 spatial regions, the tumor cells 
consisted of two distinct expression programs that were spatially segregated and 
harbored distinct copy-number alterations. The two tumor clones exhibited differences in 
gene signatures associated with epithelial-to-mesenchymal transition, MYC targets, 
hypoxia, and the expression of several cancer genes (e.g., VEGFA, AKT1, AKT2). 
Additionally, we found two distinct macrophage expression states that co-localized with 
different tumor subclones. These data demonstrate the utility of applying SNUBAR to 
delineation of the spatial organization of cell types and their expression programs in 
normal and malignant tissues to understand how spatial localization influences gene 
expression programs. This new technology is expected to have numerous applications in 
broad fields in which the spatial organization of cell types is key to understanding 
biological functions and the progression of diseased states. 
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CLINICAL/TRANSLATIONAL RESEARCH 
Radiographic and Serologic Predictors of Pathologic Major 
Response to Preoperative Therapy for Pancreatic Cancer 
Giampaolo Perri, MD1, Laura Prakash, MD1, Huamin Wang, MD2, Priya Bhosale, MD3, 
Gauri R. Varadhachary, MD4, Robert Wolff, MD4, David Fogelman, MD4, Michael 
Overman, MD4, Shubham Pant, MD4, Milind Javle, MD4, Eugene Koay, MD5, Joseph 
Herman, MD5, Michael Kim, MD1, Naruhiko Ikoma, MD1, Ching-Wei Tzeng, MD1, Jeffrey 
E. Lee, MD1, Matthew H. G. Katz, MD1 
1Department of Surgical Oncology, 2Department of Pathology, 3Department of Diagnostic 
Radiology, 4Department of Gastrointestinal Medical Oncology, 5Department of Radiation 
Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 
 
Objective: We sought to identify potential radiologic and serologic markers of pancreatic 
tumor response to therapy using pathologic major response (pMR) as the objective 
endpoint. 
 
Background: We previously demonstrated that a pMR to preoperative therapy, defined 
as detection of less than 5% viable cancer cells in a surgical sample upon 
histopathologic analysis, is an important prognostic factor for patients with pancreatic 
ductal adenocarcinoma (PDAC). 
 
Methods: Pretreatment and posttreatment computed tomography scans of consecutive 
patients who received chemotherapy and/or irradiation/chemoradiation prior to 
pancreatectomy for PDAC from January 2010 to December 2018 were rereviewed. 
Treatment response as per RECIST (version 1.1), other radiographic changes in tumor 
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size and anatomic extent, and posttreatment CA19-9 levels were compared in patients 
who did and did not have a pMR upon final histopathologic analysis of their surgical 
samples. 
 
Results: A total of 290 patients with localized PDAC underwent pancreatectomy from 
2010 to 2018 after receiving preoperative chemotherapy (n = 36 [12%]), 
irradiation/chemoradiation (n = 87 [30%]), or both (n = 167 [58%]). Among them, 28 
(10%) experienced pMR, including 9 (3%) who experienced pathologic complete 
response. Multivariable logistic regression analysis confirmed low posttreatment CA19-9 
level, partial response, and reduction in tumor volume to be independently associated 
with pMR (p<0.01). 
 
Conclusions: We identified serologic and radiographic indicators of pMR that can help 
inform the delivery of preoperative therapy to patients with PDAC. 
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Sphingosine Kinase 1 Pathway Offers Positive Therapeutic 
Targets in Triple-Negative Breast Cancer for Effective Inhibition 
of Metastasis 
Sunil Acharya, PhD1,2, Jun Yao, PhD1, Ping Li1, Chenyu Zhang, PhD1, Frank J. Lowery, 
PhD1,2, Qingling Zhang, MD1, Hua Guo, MD3, Jingkun Qu1, Fei Yang, MD, PhD4, Ignacio 
I. Wistuba, MD4, Helen Piwnica-Worms, PhD5, Aysegul A. Sahin, MD3, Dihua Yu MD, 
PhD1,2 
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX; 2Cancer Biology Program, MD Anderson Cancer Center UTHealth 
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About 10-20% of breast cancers are triple-negative, specifically, they do not express 
estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 
(HER2). Triple-negative breast cancer (TNBC) tends to occur at a higher frequency in 
younger women and is particularly aggressive, with high recurrence and metastasis 
rates. Compared with patients having other subtypes of breast cancer, TNBC patients 
have a poor overall prognosis. For example, the 5-year survival rate in patients with 
stage IV TNBC is about 22%, mainly due to early-onset metastasis. Because TNBCs 
lack expression of hormone and HER2 receptors (i.e., they are negative for therapeutic 
targets), they do not respond to and patients therefore cannot benefit from currently 
available hormone and HER2-targeted therapies. In contrast with the successful 
development of therapies for hormone receptor-positive and/or HER2-positive breast 
cancers, little progress has been made in identifying molecular targets expressed in 
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TNBCs that are druggable. Clearly, discovery of positive druggable targets in TNBCs is 
needed instead of accepting its triple-negative nontargetable status. To identify positive 
therapeutic targets in TNBC, we performed integrative bioinformatic analysis of multiple 
breast cancer patient-derived gene expression data sets and focused on kinases with 
U.S. Food and Drug Administration-approved or in-pipeline inhibitors. We identified 
sphingosine kinase 1 (SPHK1) as a top candidate. SPHK1 catalyzes phosphorylation of 
sphingosine, an amino alcohol, to generate sphingosine-1-phosphate, a novel lipid 
signaling mediator with both intracellular (as a second messenger) and extracellular (as 
a ligand for G protein-coupled receptors) functions. SPHK1 overexpression in human 
TNBC cell lines promotes spontaneous metastasis to the lungs in nude mice. Moreover, 
genetic knockdown of SPHK1 in TNBC patient-derived xenograft cells and TNBC cell 
lines decreases spontaneous metastasis to the lungs in nude mice. Using an unbiased 
approach, we demonstrated that fascin (FSCN1) upregulation contributes to SPHK1-
driven metastasis. Mechanistically, SPHK1 transcriptionally upregulates metastasis-
promoting FSCN1 gene expression via nuclear factor B (NFB) activation to promote 
metastasis. SPHK1/NFB/FSCN1 signaling pathway activation is associated with distant 
metastasis and poor clinical outcome in TNBC patients. Targeting SPHK1 and NFB 
with clinically applicable inhibitors (safingol and bortezomib, respectively), significantly 
inhibited aggressive mammary tumor growth and spontaneous lung metastasis in 
orthotopic syngeneic TNBC mouse models. These findings highlight SPHK1 and its 
downstream NFB as promising positive targets for effective therapeutic intervention for 
TNBC metastasis with fast-track clinical translation potential.  
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Poster Presentations 
A total of 62 posters were accepted for presentation during the 2019 symposium. 
Please note, only abstracts of presenters who could present during APSS and 
agreed to have their abstracts published are included. 
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Methylation of cytosines in CpG dinucleotides (DNA methylation) is an epigenetic 
mechanism with essential roles in mammalian development. Because DNA methylation 
is established during development and stably governs gene expression potential 
throughout life, it is a prime candidate mechanism in the Developmental Origins of 
Health and Disease (DOHaD). Elaborating causal pathways in DOHaD (linking early 
exposures, induced epigenetic changes, and consequent disease) is complicated, 
however, due to the inherent cell-type specificity of most epigenetic marks. We therefore 
set out to identify human genomic regions exhibiting non-tissue-specific variation, in 
other words, systemic interindividual variation (SIV), in DNA methylation. Like genetic 
variation, SIV is a potential determinant of phenotype and can be assessed in any DNA 
19 
 
 
sample that can be easily analyzed via biopsy. We designed an unbiased screen for 
human genomic regions exhibiting SIV. We performed deep whole-genome bisulfite 
sequencing of genomic DNA from tissues representing all three germ layers—endoderm 
(thyroid), mesoderm (heart), and ectoderm (brain)—from all 10 donors from the NIH 
Genotype-Tissue Expression project. We developed a computational algorithm to 
identify genomic regions at which interindividual variation in DNA methylation is 
consistent across the three tissues. After evaluating the characteristics of these regions 
using publicly available data sets, we developed a web-based application to share this 
resource with the research community. We identified 9,926 correlated regions of SIV 
(CoRSIVs). Although making up just 0.1% of the human genome, we showed that 
CoRSIVs are intercorrelated over long genomic distances, associated with transposable 
elements and subtelomeric regions, conserved across diverse human ethnic groups, 
sensitive to the periconceptional environment, and associated with genes implicated in 
various human disorders and phenotypes. We have uncovered, characterized, and 
charted a previously unexplored molecular level of human individuality. Our atlas of 
human CoRSIVs is a valuable and timely resource for population-based investigations 
into epigenetic mechanisms in the DOHaD. 
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Streptococcus pyogenes (group A Streptococcus [GAS]) is a human pathogen 
responsible for a range of diseases. From commonplace streptococcal pharyngitis to life-
threatening necrotizing fasciitis and toxic shock syndrome, GAS-related disease 
constitutes a significant human health problem. In addition to causing disease, GAS can 
asymptomatically colonize the human throat. Most GAS research is devoted to the 
mechanisms by which GAS causes disease, but substantial gaps in knowledge exist 
about the factors driving GAS transmission and colonization. The hyaluronic acid 
capsule contributes to GAS resistance to phagocytic immune cells, but GAS strains 
lacking it have been linked with enhanced colonization and persistence. To investigate 
factors like this capsule that influence colonization and transmission of GAS across 
hosts, we developed an infant mouse model of GAS intranasal colonization and 
transmission. Following intranasal inoculation with GAS, we monitored the mice for GAS 
shedding, bacterial burden, and transmission of GAS to uninoculated littermates for 11 
days. In this model, persistent intranasal colonization of infant mice was inoculum size-
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dependent, as was the shedding of GAS from the nares that occurred during the early 
phase of infection. Transmission of GAS was associated with high shedding titers during 
the early acute phase of intranasal colonization (days 1-3). Persistent shedding of GAS 
from intranasally colonized infant mice also resulted in transmission of streptococci 
across littermates. We detected differences in the rate of transmission and persistence 
across various GAS serotypes tested in our model. Similarly, the different mouse strain 
backgrounds used for inoculation (e.g., CD-1, C57BL/6J, FVB/NJ) exhibited differences 
in GAS transmission and colonization rates. We next used our model to test the 
hypothesis that the presence of the hyaluronic acid capsule inhibits transmission and 
reduces persistence by hindering adherence of GAS to host epithelia. We inoculated 
mice with a capsule-positive (M3) or capsule-negative (M87) GAS M type. Data derived 
from our model are consistent with those from human and nonhuman primate studies in 
that the presence of the capsule enhances shedding of GAS. However, the GAS capsule 
influences transmission and persistence in a strain-dependent manner. Future work 
using this model will examine the role of the capsule and other GAS virulence factors in 
manipulating the host inflammatory response, which, as evidence from studies of other 
Gram-positive pathogens suggests, is central to the transmission of bacteria colonizing 
the host nasopharynx. 
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Triple-negative breast cancers (TNBCs), representing a broad subclass of breast 
cancers lacking estrogen and progesterone receptor response and HER2 amplification, 
are refractory to hormone-based and molecularly targeted therapies, and greater 
understanding of the mechanisms that drive or contribute to TNBC subtypes is needed. 
One of the aggressive, highly malignant types of TNBC is carcinosarcoma, or 
metaplastic breast cancer (MpBC), which is composed of two tissue types: carcinoma 
(cancer of epithelial cells) and sarcoma (cancer of connective tissues or mesenchymal 
cells). Targeted treatments of TNBC in general and MpBC in particular are unmet needs. 
To accomplish this goal, one must understand how MpBCs are initiated and the 
underlying molecular mechanisms that drive progression of heterogeneous 
carcinosarcomas. Tripartite motif containing protein 24 (TRIM24) is an oncogenic 
PHD/bromo histone reader and E3 ubiquitin ligase of p53 that is frequently 
overexpressed in mammary epithelia of breast cancer patients and linked with poor 
prognosis. To determine whether TRIM24 is oncogenic in vivo, we created a mouse 
model with conditional overexpression (COE) of TRIM24 protein in mammary epithelia 
(Trim24COE). Surprisingly, TRIM24 overexpression is sufficient to drive development of 
murine carcinosarcomas (70% of all tumors, equivalent to human MpBC), which are 
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highly penetrant and lack estrogen receptor, progesterone receptor, and HER2 
expression. Preliminary results showed high expression of TRIM24 in MpBC patient-
derived tumor arrays and xenografts, supporting TRIM24 as a relevant oncogene in 
human breast cancers. These findings suggest exciting opportunities to exploit the 
Trim24COE mouse model as a means of understanding mechanisms of MpBC 
development and to create a new animal model for preclinical studies of new epigenetic-
based therapeutic approaches. Preliminary characterization of carcinosarcomas derived 
from Trim24COE mice exhibited distinct similarity with human MpBCs tumors according 
to immunohistochemistry. Furthermore, we determined the transcription profile of various 
tumor types followed by gene ontology analysis. Few of the upregulated pathways 
among tumors were epithelial-to-mesenchymal transition, glycolysis, or G2/M checkpoint 
activation. We also performed limited protein profiling of carcinosarcomas from 
Trim24COE mice using reverse-phase protein array analysis and found that epithelial-to-
mesenchymal transition is still among the top upregulated pathways according to gene 
ontology analysis. In collaboration with Dr. Nathanael Gray’s laboratory, we obtained a 
protein degrader of TRIM24, which is a potent inhibitor of the TRIM24 bromodomain. 
Preliminary analysis with the degrader of TRIM24 of carcinosarcoma-derived cell lines 
showed TRIM24 degradation within 48 hours upon treatment and decreased cell 
viability. Further studies will focus on determining the role of TRIM24 in carcinosarcoma 
both as a histone reader and as a ubiquitin ligase. We will further develop the degrader 
as a tool for a therapeutic approach for both a mouse carcinosarcoma model and human 
MpBCs. 
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In the United States, about 1 in 10 infants is born before 37 weeks of gestation (i.e., 
preterm) (Ferre et al., 2016). Prematurity increases the risk of atypical brain 
development, with cascading effects on cognitive, emotion, and language development 
(van Noort-van der Spek et al., 2012). Also, more than a third of school-aged children in 
Texas are bilingual, broadly characterized as speaking a language other than English at 
home (Kids Count Data Center, 2018). Learning two languages early in life also impacts 
cognitive, language, and brain development (Ferjan Ramirez, et al., 2016; Pons, et al., 
2015). However, bilingualism is not well understood in the preterm population. The goal 
of this investigation was to explore developmental outcomes in bilingual and monolingual 
toddlers born preterm. An additional goal was to explore links between parent behavior 
and preterm toddler outcomes in the bilingual and monolingual context. Twenty-six 
preterm toddlers (mean, 25.85 weeks gestation [standard deviation, 2.40 weeks]) with 
term-adjusted ages of 13-28 months (mean, 16.96 months [standard deviation, 4.05 
months]) participated in this study. They were categorized as bilingual (n = 11), 
monolingual (English only; n = 10), or other (no English; n = 5) based on the language or 
languages spoken at home. Parenting behavior and language use measured via dyadic 
parent-child interactions were coded using a validated protocol. In this task, a gift was 
placed on a table, and parents were told to not allow the child to open the gift for 8 
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minutes. Frequency of parental language to distract the child from the gift (e.g., singing, 
telling stories) was recorded. Each child’s cognitive skills were assessed using the 3-6-9 
box task, in which children look inside different boxes to find new toys, which requires 
remembering which boxes were already searched and choosing to search different 
ones. Finally, magnetic resonance images of 11 infants (6 bilingual, 5 monolingual) were 
acquired while they were asleep to assess their brain structures. Child language was 
measured via parent reports using the Brief Infant Toddler Social Emotional Assessment 
(Briggs-Gowan et al., 2002). The frequency of parental language distraction during the 
dyadic interaction was positively correlated with parental reports that the child “points to 
show you something far away” (r = 0.41) and with performance of the 3-6-9 box task (r = 
0.42). Performance of this task was positively correlated with gray matter volume in the 
right superior medial frontal gyrus (r = 0.46), which was positively correlated with gray 
matter volume in the right supramarginal gyrus (r = 0.57). Additionally, bilingual infants 
experienced more language distraction during the dyadic interaction (d = 2.06), higher 
parental ratings for “points to show you something far away” (d = 0.78), better 
performance on the 3-6-9 task (d = 0.78), and greater gray matter volume in the right 
superior medial frontal gyrus (d = 1.43) and supramarginal gyrus (d = 1.31) than did 
monolingual infants. These results provide preliminary evidence that bilingual preterm 
infants differ from their monolingual peers in terms of language, cognition, and brain 
structure. Both bilingual children and their parents use language differently than do 
monolingual children through pointing and distracting. Taken together, these group 
differences suggest that the language environments differentiate bilingual and 
monolingual children during development. 
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Caspase-2 is the most evolutionarily conserved of the caspase family members, which 
are well known for their involvement in apoptosis. Caspase-2 has also been implicated in 
nonapoptotic processes, including a proposed role in cell division. In several murine 
cancer models, caspase-2 knockouts demonstrated increased tumorigenesis and 
genomic instability, indicating that caspase-2 is a tumor suppressor. Additionally, 
decreased caspase-2 expression is linked with poor prognosis in patients with acute 
lymphocytic leukemia or acute myeloid leukemia, emphasizing its clinical significance. 
Due to its implicated involvement in cancer, investigation of the role of caspase-2 in cell-
cycle regulation would contribute to a better understanding the pathogenesis of cancer. 
To investigate the effects of caspase-2 on cell division, we measured the rate of cell 
proliferation in Casp2+/+ and Casp2-/- mouse embryonic fibroblasts. We observed that 
Casp2-/- cells proliferated at a higher rate than did Casp2+/+ cells as measured according 
to cell number and BrdU staining. Overexpression of Bcl-XL to block caspase-2–induced 
apoptosis failed to phenocopy the increased proliferation of the Casp2-/- cells, suggesting 
that the increase in proliferation was not dependent on the ability of caspase-2 to induce 
apoptosis. We next investigated the activation of caspase-2 during cell division by 
employing bimolecular fluorescence complementation (BiFC) to visualize the induced 
proximity of caspase-2 as an indication of the first step of activation. To accomplish this, 
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the nonfluorescent halves of the yellow fluorescent protein Venus were fused to the 
prodomain of the caspase-2 monomer. When the two monomers of caspase-2 dimerize, 
the two halves of Venus (VN and VC) reassociate and generate a fluorescent signal 
(BiFC-positive). Time-lapse confocal microscopy of cycling cells revealed a higher 
number of BiFC-positive dividing cells than nondividing cells, demonstrating that 
caspase-2 is activated around the time of cell division. Additionally, immunoblotting of 
Casp2+/+ and Casp2-/- cell lysates revealed decreased phosphorylation of the S-phase 
checkpoint proteins ATR and ATM in Casp2-/- cells following S-phase arrest. We also 
noted increased DNA damage in Casp2-/- cells by means of the DNA damage marker 
phosphorylated H2AX. Therefore, decreased activation of ATR and ATM likely reflects 
aberrant DNA replication, leading to increased DNA damage. To determine how this 
affects recovery from cell-cycle arrest, BrdU/7-AAD staining was used following S-phase 
arrest to approximate the relative percentage of cells in each phase of the cell cycle. A 
delayed exit from S phase in Casp2-/- cells was observed, further supporting that 
caspase-2 plays an important role in S-phase progression. Consistent with this, DNA 
fiber experiments demonstrated that Casp2-/- cells had an increased percentage of 
stalled forks and new replication origins. Altogether, these results support an important 
role for caspase-2 in cell-cycle regulation, potentially by means of ATR/ATM activation, 
which results in stabilized DNA replication forks, DNA repair, and proper exit from S 
phase. We propose that this mechanism may underlie the tumor suppressor function of 
caspase-2. 
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Background: Inflammatory breast cancer (IBC) is a clinically distinct and highly 
aggressive form of primary breast cancer. Although considered rare, IBC accounts for a 
significant 10% of breast cancer-related deaths due to rapid proliferation and a strong 
propensity to metastasize to distant organs. The underlying molecular mechanisms of 
aggressiveness and metastasis of IBC remain elusive. Through transcriptome profiling, 
we identified that the small leucine-rich proteoglycan gene family member decorin (DCN) 
is significantly altered in metastatic IBC sublines. The aim of this study was to 
investigate the function and mechanism of DCN in IBC tumorigenesis and metastasis. 
 
Methods: Three IBC cell lines (ER-/HER2+ [MDA-IBC3 and SUM190] and ER-/HER2- 
[SUM149]) were used in this study. DCN gene expression in clinical samples was 
analyzed using publicly available data sets and the Inflammatory Breast Cancer 
International Consortium data set. Stable overexpression of DCN in IBC cell lines 
(SUM149 and MDA-IBC3) was achieved using lentiviral vectors. For in vivo studies, 
DCN-overexpressing cell lines were injected into the cleared mammary fat pads of 
29 
 
 
SCID/beige mice, and tumor growth was monitored via caliper measurements. Tumor 
skin involvement was assessed visually during primary tumor growth and tumor excision. 
Proteomic profiling was performed using a reverse-phase protein array. Protein-protein 
interaction was analyzed via reciprocal immunoprecipitation of exogenous or 
endogenous proteins. 
 
Results: DCN expression was significantly lower in breast tumors than in normal breast 
tissue (p<0.0001), in aggressive breast cancer subtypes (p<0.0001), and in metastatic 
tumors than in primary tumors (p<0.0001). Moreover, high DCN expression correlated 
with improved overall survival (p<0.0001) and relapse-free survival (p=0.0003). In vitro, 
DCN overexpression in IBC cell lines significantly inhibited colony formation (MDA-IBC3, 
p=0.0115; SUM149, p=0.0068), migration (SUM149, p=0.0165), invasion (SUM149, 
p=0.0159), and primary and secondary mammosphere formation (primary: MDA-IBC3, 
p=0.0209; SUM149, p=0.0232; secondary: MDA-IBC3, p=0.01; SUM149, p=0.0031). In 
vivo, DCN overexpression in MDA-IBC3 cells inhibited primary tumor growth (p=0.0092) 
and reduced skin invasion (DCN control vs. DCN overexpression, 88.9% vs 33.3%; 
p=0.017 [chi-square test]). Analysis of our proteomic data on DCN-overexpressing 
SUM149 and MDA-IBC3 cells demonstrated downregulation of epidermal growth factor 
receptor (EGFR) and E-cadherin protein. Mechanistically, DCN reduced E-cadherin and 
EGFR protein expression and EGFR phosphorylation in IBC cells. Co-
immunoprecipitation demonstrated that DCN physically interacts with E-cadherin in IBC 
cell lines. DCN downregulates E-cadherin due to reduced protein stability rather than 
decreased E-cadherin mRNA expression. Additionally, E-cadherin knockdown in IBC 
cells decreased, but its overexpression increased activation of EGFR signaling without 
affecting DCN expression. Furthermore, restoring E-cadherin in DCN-overexpressing 
IBC cell lines rescued the inhibitory effect of DCN on the activity of EGFR signaling. 
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Conclusions: Our results demonstrate that DCN interacts with E-cadherin to reduce its 
protein level and suppress the EGFR signaling pathway and that this inhibits IBC 
tumorigenesis and skin invasion. Our study provides new insights into and a novel 
mechanism of IBC pathobiology that may be therapeutically targetable. Future studies 
will determine the role of DCN in IBC metastasis and the detailed mechanism of DCN-
mediated suppression of tumorigenesis in IBC patients. 
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Glioblastomas (GBMs), or grade IV gliomas, are the most recalcitrant adult brain tumors, 
afflicting about 18,000 Americans every year with a median survival duration of only 12-
15 months. Molecular classification of GBMs has shown two major subtypes—proneural 
(PN) and mesenchymal (MES)—based on gene expression patterns. Patients whose 
tumors exhibit a PN signature, or those enriched in pure PN tumor cells according to 
single-cell sequencing, exhibit markedly better overall survival than do those with the 
MES subtype. Importantly, almost all isocitrate dehydrogenase (IDH)-mutant low-grade 
gliomas (grades II and III) also exhibit a PN gene enrichment pattern and better survival 
than in patients with GBM. Of note is that a PN-to-MES switch directly contributes to 
treatment resistance. Therefore, suppressing the MES phenotype and resetting the PN 
state may be a unique therapeutic strategy for GBM. However, the molecular players 
that regulate PN gene expression in GBMs are unknown. We previously identified TAZ 
as a master transcriptional activator of the MES phenotype. We found that TAZ is 
epigenetically silenced in IDH-MUT/PN gliomas. TAZ in combination with platelet-
derived growth factor subunit B can drive conversion of low-grade PN tumors into high-
grade MES gliomas. Our preliminary investigations demonstrated that in addition to its 
transactivating functions, TAZ can cause active transcriptional repression of the PN 
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signatures, and silencing TAZ causes gain of PN signatures and increased neuronal 
differentiation. TAZ overexpression in IDH-MUT/PN GBM stem cells (GSCs) caused 
inhibition of retinoic acid neuronal differentiation, and conversely, CRISPR/Cas9-
mediated knockout of TAZ in IDH-WT/MES GSCs promoted this process as judged 
according to alteration of genes regulating neurogenesis as well as cellular morphology 
resembling neurons (dendritic branching, etc.). Our preliminary data demonstrated that 
gliomas of the TAZ-low subtype were enriched in genes defining the PN/neuronal 
lineage, whereas gliomas of the TAZ-high subtype were enriched in genes defining the 
astrocytic lineage. Genome-wide chromatin immunoprecipitation-sequencing data 
showed that overexpression of TAZ in TAZ-low cells blocks PN gene expression and 
activates the MES program by epigenetically resetting enhancers. TAZ may directly act 
as an inhibitor of gene expression, a role already shown in the literature and involving 
the formation of a complex with histone deacetylase (HDAC) proteins. In fact, pan 
inhibition of HDAC class I in IDH-WT/MES GSCs resembles, if not amplifies, the 
phenotype observed when inhibiting TAZ. Our in vivo analysis of mice bearing IDH-
WT/MES GBMs that received intraperitoneal injections of a new HDAC class i 
compound demonstrated a reduction in tumor growth and significant increase in survival. 
Taken together, our studies uncover a role for TAZ as a barrier for terminal neuronal 
differentiation and that differentiation therapy with HDAC inhibitors is possible for IDH-
WT gliomas. 
 
 
  
33 
 
 
When Will the Cancer Start? Elucidating the Correlations 
Between Cancer Initiation Times and Lifetime Cancer Risks 
Hamid Teimouri, PhD1, Maria Kochugaeva, PhD2, Anatoly B. Kolomeisky, PhD1 
1Department of Chemistry, Rice University, Houston, TX; 2Systems Biology Institute, Yale 
University, West Haven, CT 
 
Cancer is a genetic disease that results from accumulation of unfavorable mutations. As 
soon as genetic and epigenetic modifications associated with these mutations become 
strong enough, uncontrolled tumor cell growth is initiated, eventually spreading through 
healthy tissues. Clarifying the dynamics of cancer initiation is thus critically important for 
understanding the molecular mechanisms of tumorigenesis. We developed a new 
theoretical method to evaluate the dynamic processes associated with cancer initiation. It 
is based on a discrete-state stochastic description of the formation of tumors as a fixation 
of unfavorable mutations in tissues. Using a first-passage analysis, the probabilities of the 
cancer appearing and the times before it happens, which are viewed as fixation 
probabilities and fixation times, respectively, are explicitly calculated. Our model predicts 
that the slowest cancer initiation dynamics are observed for neutral mutations, whereas 
they are fast for both advantageous and, surprisingly, disadvantageous mutations. The 
method is applied to estimating the cancer initiation times from experimentally available 
lifetime cancer risks for different types of cancer. A high probability of a cancer occurring 
does not necessarily lead to a fast time for the cancer to start. Our theoretical analysis 
helps clarify microscopic aspects of the cancer initiation processes. 
 
  
34 
 
 
ENBPI Ligand for Ga-68: Synthesis, Radiolabeling Optimization, 
and Pilot Myocardial Perfusion Imaging with ECG-Gated PET 
Riccardo Muzzioli, PhD1, Federica Pisaneschi, PhD1, Seth Gammon, PhD1, David 
Piwnica-Worms, MD, PhD1 
1Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 
Houston, TX 
 
Cardiovascular disease remains the leading cause of mortality worldwide, accounting for 
31% of all deaths. Myocardial viability is a crucial and fundamental examination in 
diagnosis and prognosis in patients with cardiovascular disease and has special 
consideration for cancer patients preparing to receive regimens of chemotherapy and 
immunotherapy that may impact heart health. Specifically, myocardial perfusion imaging 
(MPI) is a noninvasive imaging technique for quantifying blood flow in the heart and is 
commonly used to define areas of reversible ischemia, characterize at-risk and infarcted 
tissue, and assess ventricular function. At present, single-photon emission computed 
tomography (SPECT) and positron emission tomography (PET) are the diagnostic tests 
most commonly used to detect coronary artery disease and provide information on 
myocardial viability. Unlike in the imaging of other organs, improving the image 
resolution in cardiac SPECT or PET remains challenging due to inherent cardiac 
contraction, respiratory movement, and body motion during image acquisition. 
Electrocardiogram (ECG)- and respiratory-gated data acquisition and analysis recover 
substantial portions of the spatial resolution loss due to cardiac and respiratory motion. 
In ECG-gated SPECT or PET MPI, cardiac cycles are divided into temporal bins 
according to the cardiac cycle. ECG-gated image data sets are formed by reconstructing 
an image of each mutually corresponding data bin and arranging these images in a 
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series. This image series represents an averaged cardiac cycle, and each image 
corresponds to a certain phase of the cycle itself. Technetium-99m–based monocationic 
radiometal complexes are the most commonly used radiotracers for myocardial SPECT 
(e.g., technetium sestamibi). However, a limited worldwide supply of molybdenum-99 
(parental isotope of technetium-99m) has stimulated research into the development of a 
novel MPI agent compatible with PET imaging. A radioisotope with excellent emission 
proprieties that can be used for PET MPI is gallium-68 (68Ga; t1/2, 68 minutes), which can 
be produced at high purity using germanium-68Ge/68Ga generators. A variety of 
multidentate ligands that form monocationic complexes have been synthetized and 
studied as myocardial imaging agents. Among multidentate ligands, Schiff base ligands 
with N4O2 binding cores are well known to coordinate various transition metals. The ENB 
ligand 1,2-ethylenediamino-bis{1-[3-isopropoxyphenyl-2-ate] methyleneamino-2,2-
dimethyl}-propane is the active hexadentate ligand that is released after imidazoline ring 
cleavage of a heptadentate precursor treated with mild acid and a trivalent metal. Upon 
complexation of Ga3+, the final complex forms a pseudo-octahedral geometry, in which 
Ga3+ is surrounded by four planar nitrogen atoms and two axial oxygen atoms. The trans 
bond average angle in the final complex is 171.6°, whereas the cis angle centered on 
Ga3+ is 90.1°, demonstrating minimal distortion from an ideal octahedral geometry and 
thus strong complexation of the metal and a highly stable radiotracer. Herein we report 
on the synthesis, radiolabeling, and characterization of 68Ga-ENB and its use as a 
radiotracer in PET/computed tomography and ECG-gated PET experiments in small 
animals as a first step toward clinical development. 
 
  
36 
 
 
Heme Activates the Inflammatory Caspases to both Positively 
and Negatively Regulate Inflammation 
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Hemolysis and increased levels of extracellular heme from red blood cell destruction 
underlie the pathophysiology of several disease states, including bacterial sepsis, 
malaria, and sickle cell disease. This hemolysis has been implicated in the inflammatory 
activation of monocytes, macrophages, and endothelial cells and often results in 
uncontrolled sterile inflammation that can augment susceptibility to infections. Heme has 
been shown to activate both TLR4 and caspase-1, potentially providing both the priming 
and activating signal to promote inflammasome assembly. Our data demonstrate that 
heme induces interleukin (IL)-1 release and that this is increased in macrophages from 
sickle cell disease patients. Furthermore, using caspase bimolecular fluorescence 
complementation, an imaging-based technique we developed to visualize caspase-
induced proximity, we showed that heme induced caspase-1, caspase-4, and caspase-5 
activation in primary human macrophages in the absence of lipopolysaccharide priming. 
In contrast, lipopolysaccharide priming was required to induce IL-1 release, suggesting 
that heme alone is sufficient to activate the inflammatory caspases but that an additional 
priming signal is required to ensure IL-1 release. Loss of caspase-1 in the THP-1 
monocytic cell line completely abrogated heme-induced IL-1 release, whereas 
caspase-5 deletion sensitized cells to heme-induced IL-1 release. This suggests that 
caspase-5 prevents IL-1 release, possibly by inhibiting caspase-1 activity, contrary to 
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the expected proinflammatory role of its homolog caspase-4. Therefore, extracellular 
heme appears to behave as a trigger for activation of inflammatory caspase-1, caspase-
4, and caspase-5, leading to both positive and negative regulation of proinflammatory 
cytokine release. Together, these studies provide insight into the molecular mechanisms 
between inflammatory caspase activation and heme-induced inflammation that may 
underlie the clinical manifestations of inflammation under nonpathogenic hemolysis 
conditions. 
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Accumulation of damaging mutations of cancer-associated genes such as BRCA1 and 
FANCG is inherent to carcinogenesis. Identifying causal mutations in a myriad of genetic 
alterations is challenging because the consequences of mutations depend on epigenetic 
contexts. The protein folding chaperones heat-shock protein 70 (HSP70) and HSP90 
represent a highly conserved and ubiquitously expressed central processing hub that 
preserves protein homeostasis and mediates cytoplasmic protein biogenesis. Recent 
work from our laboratory suggests that chaperone interactions in cells can be used as 
diagnostic tools to pre-emptively identify protein coding mutations that perturb protein 
folding. We have further tested this model by investigating the impact of breast cancer-
associated missense mutations in the C-terminal domain of the tumor suppressor protein 
BRCA1 (BRCT). To measure chaperone interactions with BRCA1-BRCT variants, we 
used a quantitative, high-throughput luminescence-based approach in living cells 
(luminescence-based mammalian interactome mapping). Mutant proteins are tagged 
with a 3x-FLAG tag epitope and transiently expressed in HEK293T cells stably 
expressing either HSP70 or HSP90 fused to a nanoluciferase reporter. Thirty-five 
previously characterized BRCT structural mutations were tested as proof of concept, 
belonging to either benign or structure-perturbing classes. Eleven of 15 benign 
mutations did not substantially bind to HSP70 or HSP90, and 18 of 20 structure-
perturbing mutations bound to chaperones at least 4.8-fold more so than did wild-type 
39 
 
 
BRCT. Intriguingly, three of the benign mutations with intermediate chaperone 
interactions compared with benign and structural mutations are known to perturb the 
intrinsic phosphopeptide-binding activity of BRCT, suggesting that quantitative 
chaperone interactions in cells can report on mutations with functional consequences. 
Chaperone binding accurately delineates between benign and structure-perturbing 
BRCT mutations (83% accuracy) and outperforms standard sequence-based 
approaches that predict the impact of missense mutations (JPRED4, 46%; PolyPhen-2, 
60%). We applied this pipeline to missense mutations of FANCG, a DNA repair factor 
associated with the cancer predisposition syndrome Fanconi anemia (FA). Chaperone 
interactions for two FA-associated mutations are enriched for HSP70 binding when 
compared with naturally occurring polymorphisms. Using a protein complementation 
assay sensitive to trimeric complex formation, we found that these FA-associated 
mutations of FANCG reduce formation of the FA repair core complex FANCG-FANCA-
FAAP20, suggesting that chaperone interactions report on structure-function 
perturbations associated with disease. Future work will measure the consequences of 
these mutations for the cancer cell phenotype in MDA-MB-436 cells. In this approach, 
saturation mutagenesis will be used to generate and compete all BRCA1-BRCT variants 
in the presence or absence of HSP90 inhibitors. Cancer mutations that depend on 
HSP90 for cell growth will be selectively depleted from the population and detected 
using deep sequencing. This approach can establish a practical approach to specifically 
targeting tumors harboring HSP90-dependent mutations that will be relevant for the 
treatment of many cancers. 
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*Co-first authors. 
 
Purpose: Radiation therapy causes DNA replication stress in cancer cells, which is 
manifested by stalled or slowed DNA replication forks and/or DNA synthesis. Unresolved 
replication stress induces DNA damage and genomic instability, ultimately leading to 
senescence or cell death. Previous studies showed that in response to replication stress, 
cells use a combination of ATM/ATR-mediated processes to restore homeostasis. 
Although the unfolded protein response has been implicated in replication stress 
response, the role of IRE1/XBP1, a major signaling branch of this response, is still 
unknown. As described herein, we investigated the contribution of IRE1/XBP1 signaling 
to maintenance of cellular homeostasis during replication stress and revealed that 
inhibition of this pathway sensitizes triple-negative breast cancer (TNBC) cells to 
replication stress and radiotherapy. 
 
Methods: To assess the role of IRE1/XBP1 in replication stress, we inhibited XBP1 
expression in MDA-MB-231 and other human TNBC cell lines using short hairpin RNA 
and evaluated the effects on cell proliferation, cell-cycle distribution, replication fork 
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progression, and fork restart after stalling. To evaluate the specific contribution of 
IRE1/XBP1 to these effects, we reintroduced XBP1 expression in cells expressing XBP1 
short hairpin RNA. To determine more precisely the dependence on IRE1/XBP1 to 
sustain replication homeostasis, we used an inducible XBP1 short hairpin RNA system 
to study the kinetics of change in these assays. To further investigate the outcome of 
XBP1 inhibition in TNBC cells during a therapeutic intervention that induces replication 
stress, we performed a comet assay to assess the accumulation of DNA damage and a 
clonogenic survival assay after radiation treatment. 
 
Results: Deficiency in XBP1 expression in TNBC cells significantly decreased cell 
proliferation. This effect was accompanied by an increased number of stalled replication 
forks and decreased ability to restart fork progression after stalling. The increased 
number of stalled forks eventually led to accumulation of single- and double-stranded 
DNA breaks. Consistent with these findings, XBP1 inhibition resulted in remarkable 
sensitivity to radiation treatment in our clonogenic survival assays. 
 
Conclusions: Although endoplasmic reticulum stress and replication stress induce 
apparently distinct cellular response machineries, significant interaction and cross-talk 
exist between the two sets of homeostasis pathways co-stimulated by stresses from the 
tumor microenvironment. TNBC cells rely on IRE1/XBP1 signaling to mitigate 
detrimental effects following replication stress. Our findings suggest that IRE1/XBP1 
inhibition and replication stress during cancer therapy reveal a novel type of synthetic 
lethality that may be exploited in cancer therapy. 
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Acute trauma or neurodegeneration in the cerebellum often leads to severe motor 
impairment and greatly diminishes the quality of life of patients with cerebellar movement 
disorders such as ataxia, dystonia, and tremor. A growing number of mouse models of 
cerebellar dysfunction recapitulate human motor disorders, with transgenic mice 
displaying either one disorder or combinations of them. In genetic and developmental 
models, motor impairments can be observed in neonates even though the cerebellar 
circuit is not fully developed until several weeks after birth. Thus far, most models have 
focused on inhibitory Purkinje cells (PCs) because they are the single output neurons of 
the cerebellar cortex and modulate cerebellar nuclear cells that connect the cerebellum 
with other parts of the central nervous system. However, the most abundant cells in the 
cerebellum are excitatory neurons, and most excitatory neurons are born after birth. 
Fast, clonal postnatal expansion of excitatory cerebellar neurons has made difficult 
manipulating their developmental mechanisms and studying their role in cerebellar 
function. The cerebellum has three types of excitatory neurons: 1) granule cells, which 
represent the most numerous cell type in the mammalian brain and directly modulate 
PCs; 2) unipolar brush cells, which are only present in specific cerebellar domains and 
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contribute to vestibular functions; and 3) excitatory cerebellar nuclei cells, which form the 
main connection between the cerebellum and cerebrum through connections with the 
thalamus. Of note, these three groups of excitatory neurons are all derived from the 
same developmental domain and require the Atoh1 gene for development. We 
selectively removed Atoh1 from cerebellar precursor cells, which diminished the number 
of granule cells, unipolar brush cells, and excitatory cerebellar nuclei cells in the 
cerebellum. Mice lacking excitatory cerebellar neurons display obvious motor 
dysfunction within the second week of life, consisting of dystonia, diminished righting 
reflexes, and action tremors that together lead to impaired mobility in the home cage and 
open field. These phenotypes are more severe in mice than a lack of neuronal signaling 
from excitatory cerebellar neurons, suggesting that excitatory neurons are essential for 
cerebellar development beyond providing electrical signals. Indeed, we found that loss of 
excitatory neurons also affects the anatomy of the cerebellum: the characteristic layered 
and foliated structure of the cerebellar cortex is absent, with PCs ectopically positioned 
anteriorly outside the cerebellum. Immunofluorescent staining showed that PCs still 
receive excitatory inputs from other brain regions, but the location of these synapses on 
the PCs is changed. Synaptic anatomical changes are supported by in vivo 
electrophysiological recordings showing that PCs do fire action potentials but that the 
pattern of these potentials is significantly altered. Taken together, excitatory cerebellar 
neurons are essential for shaping the structure and function of the neonatal cerebellum 
and are required for PC development even though most excitatory neurons are born 
after PCs. These data add to the growing body of evidence that normal cerebellar 
function during the early neonatal period is essential for establishing fundamental 
movements that are critical for early neonatal survival. 
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Olga Sizova, PhD, Tian-Hui Yang, PhD, Qing Ma, PhD, Dan Li, PhD, Lisa S. St. John, 
PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD 
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Background: Tumor microenvironments are often immunosuppressive, and tumor-
associated neutrophils play both antitumorigenic and protumorigenic roles in cancer 
progression. Neutrophil protumorigenic functions include promoting cancer cell 
proliferation and metastasis, modulation of the tumor microenvironment, and induction of 
immunosuppression. According to current knowledge, tumor-associated neutrophils can 
mediate tumor immunosuppression via secretion of 1) nitric oxide, 2) arginase-1, and 3) 
reactive oxygen species1. However, evidence that neutrophils can directly inhibit 
antitumor immune response, specifically in tumor-associated T cells, is lacking. We have 
shown that membrane-bound proteinase 3 (mP3) on neutrophils and acute myeloid 
leukemia (AML) blasts inhibits T-cell proliferation ex vivo by binding to LRP1 on 
activated T cells2. However, in vivo evidence of such signal transduction pathways is 
lacking and must be revealed. Also, how the LRP1/mP3 axis results in inhibition of T-cell 
proliferation is still unclear. We hypothesize that mP3 on granulocytes or AML blasts 
results in inhibition of T-cell proliferation upon binding to LRP1 on the surface of T cells. 
 
Methods: To understand the mechanism of LRP1-mediated suppression of T cells, we 
sought to identify the downstream signaling pathway. We used a co-culture system of 
mP3+ THP1 cells, an AML cell line, and Jurkat cells, a T-cell line that expresses LRP1, 
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as well as primary cell co-culture of donor peripheral blood mononuclear cells and 
neutrophils. 
 
Results: We are studying the in vivo effects of blocking LRP1 in tumor models of AML 
and solid cancers, such as breast cancer and melanoma, that we have established in 
our laboratory. Preliminary experiments with wild-type mice showed that mouse 
neutrophils also have the capacity to inhibit mouse T-cell proliferation. We demonstrated 
that LRP1 expression on Jurkat cells was significantly (threefold) increased upon 
CD3/CD28 activation. We confirmed using flow cytometry that mP3 expression on 
various AML cell lines, including THP1, is relevant to healthy donor neutrophils and AML 
blasts in cancer patients. We showed that co-incubation of Jurkat cells and THP1 AML 
cells at different cell ratios leads to significant reductions in Jurkat cell number and 
suppression of cell proliferation. 
 
Conclusions: We validated the physiologically relevant in vitro and in vivo model 
systems in studying LRP1-dependent T-cell suppression by mP3+ granulocytes.  
Additionally, we provided extended mechanistical insight into the mP3/LRP1 signaling 
pathway. These preliminary data support the continued study of the roles of T cells and 
granulocytes in cancer. 
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Internalization and intracellular trafficking of membrane proteins are pivotal to 
maintenance of physiological functions and drug action. However, robust, versatile 
quantitative approaches to studying such processes in real-time living systems at 
endogenous expression levels are still lacking. Herein we present two new structural 
complementation assays to quantitatively monitor membrane protein trafficking. These 
structural complementation assays are based on NanoBiT technology. The versatility 
and robustness of this approach are demonstrated by anchoring fragments of Nano 
Luciferase at the plasma membrane or in early endosomes to generate luminescent 
signals on ligand-promoted recruitment or sequestration of Nano Luciferase fragment-
tagged proteins to or from specific cell membranous systems. These assays are 
scalable to high-throughput formats and enable quantitative pharmacological studies of 
membrane protein trafficking in real time, in living systems, and at the endogenous 
expression level, allowing for elucidation of biased trafficking molecular mechanisms of 
membrane protein complexes. 
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Background: We have demonstrated that intraperitoneal injection of leucine abrogates 
lipopolysaccharide (LPS)-induced depression-like behavior in mice by blocking the L-type 
amino acid transporter 1 (LAT1)-dependent transport of kynurenine (KYN) into the brain. 
The objective of the present project is to determine whether this effect is shared by other 
amino acids, including an amino acid transported by LAT1 (phenylalanine) and an amino 
acid not transported by LAT1 (lysine). 
 
Methods: Male CD1 mice (10-16 weeks old) were housed individually with a 12/12-hour 
modified dark-light cycle. Mice were handled for 1 week and habituated to intraperitoneal 
injection and oral gavage every day for 3 days before testing. LPS (Escherichia coli 
serotype 0127:B8; Sigma, St Louis, MO) was administered intraperitoneally at a dose of 
0.83 mg/kg followed immediately by oral administration of each amino acid at a dose of 
0.76 mmol/kg. Amino acids were readministered at the same dose 6 hours later. One 
experiment in two or three replicates was run for comparing leucine with phenylalanine, 
and another independent experiment in two or three replicates was run for comparing 
48 
 
 
leucine with lysine. Each experiment was organized according to a 2 (LPS vs. saline) x 3 
(water, leucine [L6914; Sigma], phenylalanine [P2126; Sigma], or lysine [L5501; Sigma]) 
factorial design with eight or nine mice per group. The alleviating effect of leucine on LPS-
induced depression-like behavior was measured according to the duration of sniffing of 
female urine (female urine sniffing test [FUST], 5 minutes) and duration of immobility in 
the forced swim test (FST). Blood and brain samples were collected for measurement of 
KYN and tryptophan (TRP) levels at the end of the experiment. 
 
Results: LPS significantly reduced FUST activity and FUST sniffing and increased FST 
immobility. Conversely, treatment with leucine and phenylalanine reversed the effects of 
LPS on FUST sniffing and FST immobility. LPS significantly increased plasma and brain 
KYN levels and KYN/TRP ratios. These effects were attenuated by leucine and 
phenylalanine in the brain. LPS, leucine, and phenylalanine had no effect on brain or 
plasma TRP. Leucine and lysine reversed LPS-induced depression-like behavior 
measured according to decreased duration of sniffing female urine and increased duration 
of immobility in the FST. Both leucine and lysine reversed the increase in the brain 
KYN/TRP ratio induced by LPS but had no effect on peripheral markers of TRP 
metabolism. LPS, leucine, and lysine had no effect on brain or plasma TRP. 
 
Conclusions: Oral administration of leucine and other amino acids reverses LPS-induced 
depression-like behavior in mice independently of their ability to compete with LAT1-
dependent KYN transport into the brain. In ongoing studies, researchers are investigating 
the mechanisms that mediate these effects. 
 
Acknowledgements: This work was supported by Ajinomoto Co., Inc. (Tokyo, Japan) 
and the NIH/NCI under award number P30CA016672. 
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Short Illumina sequencing is the state of the art for genetics despite the fact that it 
misses 193 medically relevant genes and other genomic regions (e.g., STR, ALU), which 
have been associated with diseases. In addition, it cannot provide sufficient phasing 
information, which is crucial for diseases such as TPMT mutations to assess drug 
metabolism in a patient. Recently, long-read sequencing technologies such as those 
from PacBio and Oxford Nanopore Technologies have shown the ability to enhance the 
detection of genomic variations, including single-nucleotide variants (SNVs), structural 
variants (SVs), and methylation changes. Nevertheless, none of the studies thus far 
have detected all genomic variations, instead focusing on SNVs, SVs, or methylation 
changes. Furthermore, only a few studies have included phasing information to further 
ease the prediction of these variations onto genes and thus phenotypes. Current clinical 
and research studies therefore lack a comprehensive view of genomic variations, 
although this information is present in their sequenced data sets. Herein we introduce 
PRINCESS, a method that provides haplotype-resolved SNVs, SVs, and methylation 
changes based on a single long-read sequencing run from PacBio or Oxford Nanopore 
Technologies. PRINCESS automatically adapts itself to different coverage levels to 
optimally leverage the data set at hand. Thus, it provides comprehensive cost- and time-
efficient insight into haplotype-resolved genomic variations. This information can be 
leveraged to simultaneous study the interaction of SNVs, SVs, and methylation changes 
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and their impact on phenotypic changes. PRINCESS was evaluated based on Genome 
in a Bottle Oxford Nanopore Technologies standards and ultralong reads as well as 
PacBio Continuous Long Reads (CLRs) and Circular Consensus Sequencing data. For 1 
SMRT Cell CLR data, PRINCESS achieved 95% precision and 80% sensitivity for SNVs 
and 93% precision and 77% sensitivity for SVs on CLRs, reaching 6.9-Mb N50 phasing 
of SNVs and SVs. For 1 SMRT Cell Circular Consensus Sequencing data, it achieved 
95% precision and 90% sensitivity for SNVs and 94% precision and 79% sensitivity for 
SVs, reaching an N50 of 225 kb. PRINCESS applied to 18 PacBio with matching RNA 
sequencing data samples improved the detection of SVs (average, 22,105), SNVs, and 
phasing (average, ~5 Mb N50) and thus allowed for the detection of expression 
quantitative trait loci in an automated, fast, comprehensive fashion. 
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Dysregulated mRNA translation due to altered translation factors, regulators, or other 
components of the translation machinery is often associated with cancer proliferation, 
survival, invasion, angiogenesis, and metastasis. Therefore, the translation machinery is 
an effective target for cancer therapy. eIF4A initiation factors play an important role in 
translation initiation in eukaryotes. Pateamine A (PatA) is a marine natural product that 
inhibits cap-dependent eukaryotic translation initiation and has potent antiproliferative 
and proapoptotic activity. DMDAPatA (a simplified derivative of PatA) binds to plasma 
proteins, which limits its potency. To overcome this, a new series of PatA analogs were 
synthesized, and three new leads were identified with potent translation inhibitory 
activity. Additionally, homology models of human eIF4A1 in closed conformation were 
developed to understand the structural insights. PatA analogs were then docked to the 
predicted binding pocket, and the interactions between PatA derivatives and eiF4A1 
were studied. Our computational study results suggest that PatA and its derivatives bind 
to a pocket located between RNA- and ATP-binding pockets. PatA analogs were found 
to interact with eIF4A1 residues that directly or indirectly form nonbonded interactions 
with RNA and ATP molecules. Additionally, these compounds interact with residues at 
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the C-terminal and N-terminal domains, suggesting that they stabilize the closed 
conformation of the eIF4A receptor, which has never been proposed before. Results 
from this study will be used to develop the next generation of translation inhibitors and 
provide hypotheses to develop experiments for studying the mechanism of action of 
PatA derivatives. 
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Introduction: Understanding of tumor biology and risk stratification based on 
clinicopathologic prognostic factors has improved the selection of patients for resection 
of colorectal liver metastases (CLMs). Recently, gene mutation analysis has been 
studied for its utility in identifying patients who may benefit from CLM resection. 
However, which combination of gene mutations implicated in prognosis after CLM 
resection most precisely predicts prognosis after this surgery remains to be elucidated. 
We aimed to determine the impact of combinations of high-frequency somatic mutations 
and clinicopathologic factors on survival among patients undergoing liver resection for 
CLMs. 
 
Methods: We identified patients who underwent initial liver resection of CLMs during 
2007-2017 and had multiple gene mutation data available. Risk factors and hazard ratios 
(HRs) for overall survival (OS) and recurrence-free survival (RFS) were determined 
using Cox proportional hazards models. 
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Results: Of 1,462 patients who underwent CLM resection during the study period, 507 
met inclusion criteria. Multigene testing revealed that mutation rates were higher than 
10% for TP53 (70.8%), APC (53.5%), RAS (50.7%), PIK3CA (15.8%), and SMAD4 
(11.0%). BRAF was mutated in 2% of patients. Mutations of BRAF, RAS, TP53, and 
SMAD4 were significantly associated with poor OS together with clinicopathologic 
factors (largest CLM diameter and surgical margin status), and mutations of RAS, TP53, 
and SMAD4 were significantly associated with poor RFS together with demographic and 
clinicopathologic factors (age, number of CLMs, largest CLM diameter, prehepatectomy 
chemotherapy >3 months, extrahepatic disease, and surgical margin status). Patients 
with triple mutations of RAS, TP53, and SMAD4 had a significantly worse median OS 
duration (2.3 years) than did patients with double mutations (KRAS, TP53, or SMAD4; 
4.5 years [HR, 3.21]; p<0.001), those with single mutations (6.9 years [HR, 6.0]; 
p<0.001), and wild-type patients (7.8 years [HR, 8.61]; p<0.001). In turn, double 
mutations conferred significantly worse OS than did single mutations (HR, 1.88; 
p<0.001) and wild-type status (HR, 2.68; p=0.002). Patients with RAS mutations and 
wild-type for TP53/SMAD4 had OS and RFS durations that were not significantly 
different from those in patients wild-type for RAS (HR, 0.95; p=0.858 and HR, 1.06; 
p=0.729, respectively). 
 
Discussion: Double or triple mutations of RAS, TP53, and/or SMAD4 are associated 
with worse survival and recurrence than are mutations of only one or none of these 
genes after resection of CLMs. RAS mutation status alone is not sufficient for precisely 
predicting prognosis. These findings may be useful for clinical decision-making for 
patients with tumor characteristics associated with poor prognosis and for risk 
stratification of patients in future clinical studies. 
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High-grade gliomas (HGGs), including the most common primary brain tumor, 
glioblastoma, may arise from malignant transformation of low-grade gliomas (LGGs). 
Whereas LGGs are often clinically indolent, glioblastomas have dismal outcomes 
despite maximal therapy. Accumulating data suggest that chemokine signaling directly 
contributes to malignant progression of LGGs by altering tumor behavior or impacting 
the immune microenvironment. As described herein, we examined the role of CX3CR1 
signaling in malignant transformation of LGGs. First, patients with malignantly 
transformed LGGs were genotyped for the presence of the common loss-of-function 
CX3CR1 V249I polymorphism, and median overall survival was compared according to 
genotype. Second, RNA sequencing data were analyzed for differential gene expression 
based on genotype. Third, surgical samples were examined for altered expression of M2 
macrophage markers and microvessel density among the genotypes. Fourth, a 
genetically engineered murine model was leveraged to model endogenous intracranial 
gliomas with targeted expression of CX3CL1 and CX3CR1 individually or in combination. 
Our data demonstrated that heterozygosity (V/I) and homozygosity (I/I) for the loss-of 
function CX3CR1 polymorphism are associated with markedly better median overall 
survival in patients with LGGs that have transformed to HGGs than in those with the 
wild-type genotype (V/V). In addition, HGGs from patients with the V/I or I/I genotype 
exhibited significantly decreased levels of CCL2, which is important for the recruitment of 
M2 macrophages, as well as decreased levels of ANGPT1 and MMP9, which mediate 
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angiogenesis. This correlates with reduced intratumoral accumulation of CD204-positive 
macrophages and microvessel density in tumors from V/I and I/I patients. Finally, in an 
RCAS-PDGFB–driven model of LGG, co-expression of CX3CL1 and CX3CR1 promoted 
a more malignant tumor phenotype and shorter tumor-free survival. Taken together, our 
results demonstrate that CX3CR1 signaling promotes malignant transformation of LGGs 
via accumulation of glioma-associated M2 macrophages and increased angiogenesis. 
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The purpose of this study was to determine the types, proportions, and energies of the 
secondary radiation interactions in a Compton camera (CC) during the delivery of a 
clinical proton beam. The delivery of a 150-MeV clinical proton pencil beam incident on a 
water phantom was simulated using Geant4 software. The simulation included a CC 
matching the configuration of a Polaris J CC designed to image prompt gammas (PGs) 
emitted during proton beam irradiation for the purpose of in vivo range verification. The 
interaction positions and energies of the secondary radiation (gamma rays, x-rays, 
electrons, positrons, neutrons, and protons) were scored. The total number of secondary 
particles that reached the CC was found to be 157,826 counts per 10^8 protons (~1 Gy 
of dose to water). The most abundant particles were gamma rays (49.0%), neutrons 
(41.0%), and electrons (8.7%). The gamma rays included six major types: PGs that did 
not scatter before reaching the CC detector modules, PGs that were scattered in the 
target and/or CC box before reaching the detector modules, PGs produced from 
neutron-inelastic interactions, annihilation gammas, gammas produced by the neutron 
capture process, and radioactive-decay gammas. Only 79% of the radiation that reached 
the camera was found to interact in the detector modules. The amount of secondary 
radiation of each particle type received by each of the CC detector modules was found 
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to change as a function of the module’s position with respect to the beam and/or the 
position of the Bragg peak in the target. The detector modules located in the first stage, 
proximal to the target, absorbed the majority of the charged secondary radiation and 
low-energy photons. The particle abundance of secondary neutrons and prompt 
gammas in two detector stages was almost constant. The count rates were lowest in the 
distal modules and maximal in the modules closest to the Bragg peak, ranging from 
6,629 to 13,747 counts per 10^8 protons. Strategies for using CCs for proton range 
verification should include methods of reducing the large neutron backgrounds and low-
energy non-PG radiation. The proportions of interaction types by module may provide 
information useful for background suppression. 
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Prostate Cancers by Altering a Conjugation Switch that Controls 
ATG12–ATG5-ATG16L1 Complex Formation 
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Murine tumor models suggest that autophagy maintains homeostasis by delivering a 
variety of potentially oncogenic intracellular substrates to lysosomes for degradation, 
including excess and aberrant organelles, protein aggregates, and invading pathogens. 
Conversely, autophagy is reportedly activated as a survival mechanism in tumor cells in 
response to nutrient, oxidative, chemotherapeutic, and other stresses commonly found 
in the tumor microenvironment. Together, this suggests that autophagy paradoxically 
suppresses malignant transformation of normal cells while promoting progression and 
metastasis of tumor cells. Thus, inhibition of autophagy in tumor cells has intriguing 
therapeutic potential. However, the mechanisms by which autophagy is regulated during 
human tumorigenesis and the effects it has on tumor progression and metastasis are 
poorly understood. Of note, the 6q21 chromosomal locus containing the essential 
autophagy gene, autophagy-related 5 (ATG5), is among the most frequently deleted 
regions in human prostate cancer (PCa), and we have determined that ATG5 mRNA 
expression is markedly lower in both primary prostate tumors and metastases than in 
normal prostate tissue. The reintroduction of ATG5 into deficient prostate tumor cells 
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dramatically suppressed xenograft tumor growth, which, in contrast with murine tumor 
models, suggests that autophagy suppresses both the initiation and progression of PCa. 
In cells, ATG5 binds to ATG16L1 and is covalently conjugated to the ubiquitin-like 
protein, ATG12, to form the heteromeric ATG12–ATG5-ATG16L1 complex, which 
mediates autophagosome formation. We discovered that numerous somatic ATG5 
mutations identified in both primary prostate tumors and metastases as well as 
upregulation of dominant-negative ATG16L2 expression inactivate autophagy by directly 
disrupting the essential ATG5-ATG16L1 interaction, which prevents ATG12 conjugation 
and instead triggers ubiquitin conjugation and proteasomal degradation of ATG5, 
ATG12, and ATG16L1. Thus, we discovered that ATG12–ATG5-ATG16L1 complex 
formation and autophagy are tightly regulated by a conjugation switch formed by the 
competing ATG12 and ubiquitin conjugation reactions that target ATG5. We determined 
that this conjugation switch mechanism is directly altered through multiple unique 
mechanisms in both primary prostate tumors and metastases, which suggests that use 
of autophagy inhibitors is likely contraindicated in the treatment of PCa. 
 
Supported by the NIH (CA129521 and GM096101), the NIEHS (T32ESO7247), and MD 
Anderson (Institutional Research Grant). 
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The G-quadruplex is a noncanonical DNA secondary structure formed by four DNA 
strands containing multiple runs of guanines. The G-quadruplexes play an important role 
in DNA recombination, replication, telomere maintenance, and transcription regulation. 
Small molecules that stabilize the G-quadruplexes alter gene expression in cancer cells. 
We hypothesized that the G-quadruplexes regulate transcription in neurons. We 
discovered that pyridostatin, a small molecule that specifically stabilizes G-quadruplex 
DNA complexes, induced neurotoxicity and promoted the formation of DNA double-
strand breaks in cultured neurons. We also found that pyridostatin downregulated 
transcription of the Brca1 gene, which is critical for double-strand break repair. 
Importantly, in an in vitro gel shift assay, we discovered that an antibody specific to the 
G-quadruplex structure binds to a synthetic oligonucleotide, which corresponds to the 
first putative G-quadruplex in the Brca1 gene promoter. Together, our results suggest 
that the G-quadruplex complexes regulate transcription in neurons. Studying the G-
quadruplexes could represent a new avenue for neurodegeneration and brain aging 
research. 
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The parasitic protozoan Trypanosoma brucei possesses a motile flagellum that also 
determines cell morphology, defines the cell division plane, and mediates cell-cell 
communications. Inheritance of the newly assembled flagellum during the cell cycle is 
controlled by the polo-like kinase homolog TbPLK, which also regulates cytokinesis 
initiation. TbPLK localizes to multiple cytoskeletal structures such as the basal body, 
bilobe, and distal tip of the newly assembled flagellum attachment zone (FAZ) filament. 
TbPLK functions upstream of the signaling pathway and recruits numerous downstream 
cytokinesis regulators. Mechanistically, how TbPLK is targeted to its subcellular 
locations to execute its multiple functions remains poorly understood. Herein we report 
on a novel trypanosome-specific protein named BOH1 that interacts and cooperates with 
TbPLK to regulate flagellum inheritance and cytokinesis initiation. BOH1 localizes to an 
unusual subdomain in the bilobe structure, bridging the hook complex, centrin arm, and 
FAZ filament. Depletion of BOH1 disrupts the hook complex morphology, inhibits centrin 
arm elongation, and abolishes assembly of the FAZ, leading to flagellum detachment 
and mispositioning. Furthermore, BOH1 deficiency impairs localization of TbPLK and the 
cytokinesis regulator CIF1 to the new FAZ tip, providing the molecular mechanism for its 
role in cytokinesis initiation. These results demonstrate the requirement of BOH1 for 
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maintaining bilobe morphology and regulating flagellum inheritance and identify BOH1 
as an upstream regulator of the TbPLK-mediated cytokinesis regulatory pathway. 
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In a cohort study of HIV-infected individuals followed for the onset of AIDS, the period 
from HIV infection to the onset of AIDS, referred to as the incubation period for AIDS, is 
of main interest. However, it is often difficult to ascertain due to HIV infection onset 
timing/date uncertainty. An additional complication is that the observed HIV-infected 
subjects are likely to have long incubation periods for AIDS. We demonstrated how to 
estimate distribution of the incubation period of AIDS with the uncertain HIV infection 
onset subject to left-truncation and right-censoring. Estimation of the underlying 
incubation period from the HIV/AIDS cohort data is handled within a general, flexible, 
parametric modeling framework. The generalized odds-rate class of regression models, 
which consists of widely used models, proportional hazards, and proportional odds 
models, is considered in assessing the association of risk factors with the incubation 
period for AIDS. In simulation studies, we assessed the finite sample performance of the 
model fitting and hazard function estimation. We applied the proposed method to data 
from an HIV/AIDS study on intravenous drug users admitted to a detoxification program 
in Badalona, Spain. 
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In clinical science, researchers often aim at identifying the bacterial taxa associated with 
a continuous outcome. However, these bacterial taxa are dependent on each other in a 
phylogenetic tree that is generated based on DNA sequence similarities. These 
dependences bring difficulties to regular variable selection techniques. We tackled this 
problem using a Bayesian variable selection framework by considering the phylogenetic 
tree as a graphical prior and formulated an Ising prior on the model space to incorporate 
structural information on candidate variables. Additionally, microbiome compositions are 
often defined as sparse vectors of proportions with unit sums, which are difficult to 
handle statistically because of both the large number of coordinates equal to zero and 
constraint on the sum of coordinates. We proposed two methods to relax the constraint 
by transforming the parameter space: contrast transformation and generalized 
penalization. We showed that our methods outperformed Weilin's LASSO method in 
different simulation scenarios. An application with COMBO 98 data showed the 
usefulness of our proposed model when linking the microbiome with BMI. 
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Microelectronic devices with integrated engineered proteins/microbes take advantage of 
the tools of synthetic biology and microelectronics to combine the sensitivity of genetic 
networks with the functionality of microelectronic devices. For example, synthetically 
engineered microbes/proteins can respond to target molecules with a measurable output 
and can be incorporated into not only in vitro and in vivo biosensors but also highly 
sensitive detectors for environmental pollutants. This study is based on both 
electrochemical/organic electrochemical transistor-based screening with encapsulated 
protein switches/engineered microbes. The electrochemical measurements of 
metalloproteins incorporated in these devices have demonstrated a 20-fold increase in 
the current response over those in previous reports. In addition, high reproducibility of 
redox behavior of the proteins in multiple cycles indicates the effective binding of 
proteins to the electrode contacts and stability proteins in the newly optimized Nafion-
based electrolytes that host the proteins. The ability to activate the protein switches to 
generate an electrical response and changes in redox behavior with the introduction of 
molecules that must be screened is the basic principle behind this approach. The 
proposed sensors are in the process of being improved on a scale of sensitivity and 
device architecture to form an array of sensors for simultaneous detection of multiple 
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target molecules. Future goals of this project include creating portable/wearable 
electronics for on-site monitoring in environmental studies and medical devices. 
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Novel Derivatives of Anaplastic Lymphoma Kinase Inhibitors: 
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Fluoroethyl Analogues of Crizotinib, Alectinib, and Ceritinib 
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Objectives: Anaplastic lymphoma kinase (ALK), an oncogenic receptor tyrosine kinase, 
has emerged as a therapeutic target in various cancers, especially non-small cell lung 
cancer. Although several ALK inhibitors have gained regulatory approval, clinical 
evidence indicates that their long-term benefit is often limited by the acquisition of 
resistance derived from secondary point mutations in the target. Importantly, some 
members of this class of compounds are unable to cross the blood-brain barrier, 
preventing efficacy against brain metastases. Herein we report on the fluoroethyl 
analogs of crizotinib, alectinib, and ceritinib as potential drug candidates with improved 
brain penetration. 
 
Methods: The three analogs were synthesized using fluoroethyl tosylate coupled with 
crizotinib, alectinib, and ceritinib, respectively. In cellulo cytotoxicity screening was 
performed with H2228 ALK-positive lung cancer cells and H441 ALK-negative lung 
cancer cells. The F-18 fluoroethyl analogs of crizotinib (18F-FECrizotinib) and ceritinib 
(18F-FECeritinib) were synthesized using [18F]fluoroethyl tosylate coupled with crizotinib 
and ceritinib, respectively. 18F-FEAlectinib was synthesized from mesylate or tosylate 
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precursors via direct fluorination with 18F-fluoride. To study the fluoroethyl ALK inhibitor 
pharmacokinetics in vivo, positron emission tomography was performed using the 
respective F-18–radiolabeled analogs in healthy nude mice. 
 
Results: The cytotoxicity of the fluoroethyl analogs manifested in ALK-positive H2228 
cells at nanomolar potency with no significant change compared with the parent 
compounds. We obtained the F-18 fluoroethyl analogs of ALK inhibitors with good yields, 
high purity, and high specific activity. Positron emission tomography in healthy mice 
showed significant early brain uptake (%ID/cc) for the series as a whole (18F-
FECrizotinib %ID/cc, 6.6 ± 2.6; 18F-FEAlectinib %ID/cc, 8.1 ± 2.6; 18F-FECeritinib 
%ID/cc, 6.6 ± 1.8 at 5 minutes after injection), suggesting penetration of the blood-brain 
barrier. 
 
Conclusion: These novel fluoroethyl ALK inhibitor analogs show promise for enhanced 
blood-brain barrier penetration and therapeutic potential in the central nervous system. 
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Background: Aurora kinases regulate mitosis and are often upregulated. Our group and 
others have proven that MYC-driven small cell lung cancers (SCLCs) are vulnerable to 
treatment with aurora kinase A inhibitors, but their use is limited by toxicity due to high 
aurora kinase A expression. Aurora kinase B (AURKB) levels are variable in SCLCs, 
making AURKB an attractive therapeutic target. A novel AURKB inhibitor, AZD2811NP 
(nanoparticle), is now being investigated in relapsed SCLC patients (NCT02579226). We 
hypothesize that molecularly defined subsets may be sensitive to treatment with 
AZD2811. 
 
Methods: We tested 50 human-derived SCLC cell lines with AZD2811 in 96-hour 
proliferation assays. To identify translatable biomarkers of response, we correlated half-
maximal inhibitory concentration (IC50) values with genomic (whole exome sequencing), 
transcriptomic (RNA sequencing), and proteomic (reverse-phase protein array) profiling. 
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Results: AZD2811 was active in a subset of SCLC cells: 13 of 30 (43%) had high 
sensitivity (IC50, <30 nM; Cmax), and 7 of 30 (23%) had intermediate sensitivity (IC50, 30-
100 nM). Comparing protein expression, we found that cMYC (fold change [FC], 2.5; 
p=0.015) and vimentin (FC, 1.66; p=0.022) were top biomarkers of sensitivity, whereas 
high E-cadherin (FC, 1.94; p=0.046) and BCL-2 (FC, 1.86; p=0.032) levels were 
associated with resistance. Of note, among 13 highly sensitive cells, only 5 
overexpressed cMYC, highlighting that activity of AURKB inhibitors is not limited to 
MYC-driven SCLC. Indeed, among recently described transcription factor-defined 
subsets of SCLC, a majority of the NEUROD1-defined subset (cMYC-enriched) was 
sensitive to treatment with AZD2811 (25% of ASCL1-defined and 67% of POU2F-3–
defined subsets). These data suggested that the ASCL1-defined subset includes 
heterogeneous subgroups that require further analysis to dissect their molecular 
features. Mutations in EP300, a histone acetyltransferase that controls chromatin 
modification and transcription, also predict sensitivity. 
 
Conclusions: Our results show encouraging single-agent activity of AZD2811 in SCLC 
cells in vitro and suggest a novel biomarker-driven approach for combinations. 
Candidate biomarkers will be tested using samples from an ongoing clinical trial. The 
high BCL-2 levels observed in resistant cells provide a rationale for exploring 
AURKB/BCL-2 inhibitor combinations. 
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Background: Mutations of TP53 are associated with low response rates for standard 
therapy and poor outcomes in patients with acute myeloid leukemia (AML). Combination 
therapy with the BCL2 inhibitor venetoclax (VEN) has emerged as an effective option for 
AML. 
 
Methods: Patients with TP53-mutated AML treated with VEN from 2014 to 2018 were 
reviewed. Mutation testing was performed using a whole-exome next-generation 
sequencing panel. Patient characteristics, responses to therapy, and outcomes were 
analyzed. 
 
Results: We identified 69 patients with TP53-mutated AML treated with VEN: 36 (52%) 
in the front-line setting and 33 (48%) in the salvage (R/R) setting (Table 1). The median 
follow-up durations were 4.5 months (range, 0.5-48.5 months) and 8 months (range, 1.0-
46.5 months) for front-line and R/R patients, respectively. The karyotype was complex in 
32 (89%) and 29 (88%) patients in the front-line and R/R cohorts, respectively. In the 
R/R cohort, the number of median prior treatments was two (zero to eight). VEN was 
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given in combination with 1) hypomethylating agents (HMAs; 87%), 2) FLAG-Ida (3%), 
3) low-dose ara-C (4%), or 4) CPX-351 (6%). The overall response rates (ORRs) were 
47% and 24% in the front-line and R/R patients, respectively. All six patients with 
negative minimal residual disease had complete cytogenetic responses after taking 
VEN. Some remained in complete remission (CR) for a median of 3.4 months (range, 
1.7-4.7 months). Two patients (both R/R) underwent allogeneic stem cell transplantation. 
 
Conclusion: VEN-based therapy had ORRs similar to those of HMAs alone but higher 
CR rates in patients with TP53-mutated AML. Larger studies with longer follow-up are 
needed to determine the role of VEN-based therapy in this difficult subset. 
 
Characteristics Front-line (n=36) R/R (n=33) n (%) / Median (range) n (%) / Median 
(range) 
Age (years) 74 (30-86) 67 (22-85) 
Bone marrow blasts 25 (6-88) 32 (6-86) 
Secondary AML 11 (31%) 4 (12%) 
Therapy-related AML 10 (28%) 6 (18%) 
Karyotype 
Complex (≥3 abnormalities) 32 (88%) 29 (88%) 
Diploid 1 (3%) 1 (3%) 
Other 3 (9%) 3 (9%) 
VEN combination 
VEN + HMAs 33 (91%) 27 (82%) 
VEN + FLAG-Ida 0 2 (6%) 
VEN + LDAC 3 (6%) 0 (3%) 
VEN + CPX-351 1 (3%) 3 (9%) 
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Response 
CR 13 (36%) 5 (15%) 
CR without count recovery (CRi) 4 (11%) 3 (9%) 
ORR (CR/CRi) 17 (47%) 8 (24%) 
Minimal residual disease Negative 5 (14%) 1 (3%) 
Median overall survival duration (months) 3.6 2.5 
6-month OS 36% 27% 
Median CR duration (CRD) (months) 6.4 3.6 
6-month CRD 51% 22% 
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Background: In 2016, the percentage of nonwhite transgender individuals was 
estimated to be 45%, which is higher than the percentage of nonwhite individuals in the 
nontransgender population1,2. However, ethnic representation through published images 
may not accurately represent the racial diversity among transgender people, as image 
selection can be subjective to authors’ unconscious biases. Representation in the 
literature may thus tend toward pre-existing racial iniquities and influence the 
accessibility, delivery, and quality of transgender health care3. 
 
Aim: The objective of this study was to determine if published figures across the gender-
affirming literature accurately reflect the racial demographics of transgender individuals. 
 
Method and Measures: A search of all transgender health publications up to 2018 for 
photographs and rendered graphics depicting human skin was conducted. For each 
image, skin tone was categorized as light (1-2), medium (3-5), or dark (6-10) based on 
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the Massey-Martin scale. Proportional data and average number of dark images per 
article were compared. Regression analyses were performed to assess the correlation of 
time and geographic region on nonwhite images. 
 
Results: In total, 2,022 photographs and 288 graphics from 291 articles were analyzed, 
the majority of which were of European origin (62.1%). Dark skin images represented 
7.1% of photographs and 6.2% of graphic illustrations. The mean number of 
photographs per article with light skin was 4.9 compared with 1.5 and 0.5 with medium 
and dark skin, respectively (p<0.001). International publications were less likely to 
publish photographs of dark skin than were American publications (r=-0.317; p<0.001). 
Furthermore, a significant decrease in dark skin photographs over time was 
demonstrated (r=-0.118; p=0.046). 
 
Conclusions: Although the ethnic diversity of the transgender population has been well 
documented, racial minorities remain underrepresented across the literature, causing 
further marginalization of these groups. Representation of diversity in the literature is 
only one piece of the racial inequities in health care and should be addressed by 
dispelling implicit biases and cultural competencies. Moving forward, published images 
should better represent the true racial composition of transgender individuals. 
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Introduction: Tumor heterogeneity is a hallmark of cancer, and its underlying clinical 
relevance has been well established across different tumor types. In the context of 
estrogen receptor (ER)-positive breast tumors, variation in ER expression among 
different tumors or distinct cell populations within a single tumor are predicted to account 
for differences in clinical behavior, treatment response, and disease recurrence. 
However, a clear understanding of the molecular and cellular mechanisms of tumor 
heterogeneity that are relevant to the prognosis and therapy for early-stage ER-positive 
breast cancer has not been established. Previous results of bulk RNA sequencing (RNA-
seq) of ER-positive biopsy samples represent an average of gene expression patterns; 
this may obscure biologically relevant differences between cells. Single-cell RNA-seq 
(scRNA-seq) is an approach to overcoming this problem, allowing for assessment of 
intratumoral cell populations and biological systems at unprecedented resolution. In this 
study, our aim was to compare gene expression profiles for bulk RNA-seq and scRNA-
seq of tumor biopsy samples in early-stage ER-positive patients. 
 
Methods: Tumor and normal tissue biopsy samples obtained from ER-positive patients 
were divided into three parts: two dissociated by enzymatic disaggregation and one by 
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direct total RNA isolation. Tumor samples were subjected to both scRNA-seq and bulk 
RNA-seq analyses, whereas a single-cell suspension of normal matched tissue was 
used for bulk RNA-seq alone. Furthermore, patient-derived organoids were generated 
from both normal and tumor samples. Single-cell isolation and barcoding were assessed 
using the 10x Genomics technology followed by RNA-seq with the Illumina NovaSeq 
6000 system (50PE), whereas bulk RNA-seq was performed using an Illumina PE150 
strategy. 
 
Results: Our preliminary data represent an assessment of tumor and adjacent normal 
tissue samples collected after mastectomy from an 80-year-old ER-positive, 
progesterone receptor-positive, HER2-negative patient diagnosed with early-stage 
infiltrating ductal carcinoma in situ (stage IB). ScRNA-seq of tumor tissue from this 
patient identified 10 distinct clusters of cells consisting of both immune and nonimmune 
stromal populations (epithelial cells, endothelial cells, fibroblasts, and immune cells). 
Ninety-five percent of single cells were luminal. However, a small group (2%) of cells 
had a basal-like signature, which can lead to disease recurrence. Of note, although the 
patient was clinically characterized as HER2-negative according to 
immunohistochemistry and fluorescence in situ hybridization, we observed HER2 
overexpression in the vast majority (95%) of isolated single cells. Furthermore, organoid 
cultures recapitulated the features of patients' tumors and presented similar 
transcriptomic profiles. We have adapted similar sequencing and downstream analyses 
for an additional number of patient biopsies. Our ongoing study is geared toward 
comparing bulk and single cell transcriptome profiles from these ER-positive cases and 
identifying overlapping populations that can predict recurrence or novel therapeutic 
vulnerabilities. 
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Conclusions: Bulk RNA-seq approaches lack the resolution needed to visualize the true 
extent of stromal heterogeneity and may mask rare populations or cellular phenotypes 
that could be critical for tumor survival. ScRNA-seq highlights the dynamic and adaptive 
nature of all cellular populations within an evolving tumor microenvironment and reveals 
potential cross-talk between these two compartments. Lastly, establishment of organoid 
cultures presents the opportunity for high-throughput drug screening studies and the 
identification of new patient-tailored therapeutic strategies. 
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Gap junctions in the retinal inner plexiform layer play an important role in quick vision 
adaption to light through synaptic networks. The electrical coupled network via connexin 
36 (Cx36) gap junctions is modifiable via interaction with Ca2+/calmodulin-dependent 
kinase II. Herein we describe a highly controlled multiloop circuit in which Cx36 gap 
junctions are in contact with calcium. In compliance with a protocol approved by the 
Institutional Review Board of The University of Texas Health Science Center at Houston, 
transgenic Cx36-GCaMP mice were used for calcium live imaging and immunostaining. 
Through baseline fitting, changes in GCaMP fluorescence were measured using area 
under the curve and analyzed using mixed linear models in RStudio. Administration of 
an N-methyl-D-aspartate (NMDA) receptor inhibitor or blocker of L-type calcium 
channels significantly reduced the confluence of calcium (indicated by GCaMP 
response) in proximity to Cx36 gap junctions upon the stimulatory input of glutamate and 
glycine. In contrast, GCaMP response toward -amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) input was significantly reduced by the inhibition of 
GABAA receptors, suggesting that increasing excitatory synaptic activity leads to a 
decrease in synaptic AMPA receptors. Finally, the rates of co-localization of Cx36-
GCaMP protein with immunostained GluR2/3 and NMDA receptor 1 were 43.6% and 
62.3%, respectively. These results demonstrated the roles of glutamatergic receptors in 
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regulating calcium influx at Cx36 gap junctions. In conclusion, the calcium influx elicited 
by AMPA receptor activation correlates with the opening of GABA receptors, presumably 
via membrane hyperpolarization-induced AMPA receptor retention. In addition to the 
interplay of AMPA and GABA receptors, excitatory postsynaptic potential-induced 
calcium influx was dependent on the activity of NMDA receptors and L-type calcium 
channels. This study of calcium dynamics provides insight into how electrical synaptic 
transmission is regulated in the locality of Cx36 gap junctions. This project was 
supported by a National Eye Institute grant (R01EY012867). 
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Background: Acral lentiginous melanoma (ALM), a rare subtype of cutaneous 
melanoma (CM), is of particular interest because it is more aggressive and treatment-
resistant than nonacral CM. 
 
Method: The gene expression profiles of 19 ALM and 10 nonacral CM tissue samples 
(formalin-fixed, paraffin-embedded) banked from 2008 to 2019 at The University of 
Texas MD Anderson Cancer Center were assessed using NanoString technology with a 
PanCancer Immune Profiling Panel. 
 
Results: Of the patients with ALM, 15 were white, 3 were Hispanic, and 1 was Asian. Of 
the 10 nonacral CM patients, nine were white, and one was African American. Eighteen 
patients (62%) were male, and the mean patient age was 62 years (range, 2-92 years). 
The volar surface was the most common anatomical site of ALM (n = 17 [89%]). Of note, 
we found similar expression of inhibitory immune-regulatory genes in both acral and 
nonacral CM (CTLA4, CD274, PD-L2, FoxP3, and p53). Gene expression analysis 
showed that hallmark melanoma genes (MAGEA12 and PRAME) were similarly 
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expressed in acral and nonacral CM. Furthermore, gene expression associated with 
cytotoxic T cells (CD3G, CD8, IFN, PRF1, GZMB, and GZMA), natural killer cells 
(KLRD1 and KLRG1), and macrophages (CD68 and CD163) did not differ significantly in 
ALM and CM (p>0.1). In addition, we found higher expression of the IL-6 gene in primary 
ALM than in primary nonacral CM (p=0.01). Nine primary ALM patients (47%) had 
distant metastasis. We found high expression of IL-6 in eight primary ALM patients 
(42%). Seven of these eight patients (88%) had metastatic relapse, compared with two 
of nine patients who had low expression of the IL-6 gene (p=0.01). 
 
Conclusions: In our preliminary data, we found high expression of the IL-6 gene in 
primary ALMs in most patients who had distant metastasis. IL-6 could be a negative 
clinical prognostic factor for patients with primary ALM. Additional studies with larger 
samples are necessary to validate these findings. 
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Background: With the increasing cultural awareness of gender diversity, transgender 
individuals are becoming more likely to present in general health care settings. In 
addition to traditional health care, patients in this population have unique needs related 
to gender transitioning. Whereas challenges related to health care utilization in this 
population have been discussed, studies examining health services in the Medicaid 
population are limited. 
 
Aim: In this study, we addressed this knowledge gap by investigating transgender 
patients’ use of health care services, including behavioral therapy, primary care, 
endocrinology, and surgery, in a Medicaid managed care program. 
 
Methods and Measures: Following our institution’s Institutional Review Board approval, 
a retrospective review of all patients who presented for any service billed to health 
insurance with gender identity disorder or gender dysphoria from 2013 to 2018 was 
performed. Our health plan is a Medicaid managed care organization serving almost 
430,000 members in one of the largest urban areas in the United States. Information 
regarding patient demographics and health care services was reviewed. The utilization 
rates of distinct services and interventions were analyzed. No community participation 
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was performed. For age subanalysis, patients were placed in three groups: early 
adolescents (<16 years old), late adolescents (16-18 years old), and adults (>18 years 
old). 
 
Results: We identified a total of 192 patients with 787 documented encounters. The 
mean patient age was 15.0 years (3.8-28.8 years), and the majority were early 
adolescents (57.8%). Assigned gender at birth was as follows: 70 male and 122 female. 
The mean number of encounters per patient was 4.1 (1.0-74.0). Early adolescents had 
the highest number of encounters followed by late adolescents and adults. Behavioral 
health services were the most commonly used (50.0%) followed by primary care 
(47.4%). Endocrinology and surgical services were encountered by 2.1% of the patients 
and no patients, respectively. Medications were prescribed for 25% of the population; 
the majority were behavioral health medications. Hormonal treatment was prescribed for 
6.7% of the patients. 
 
Conclusion: Gender identity is not a binary concept, and individuals with gender 
dysphoria or who identify differently from their assigned gender are an underserved 
population with unique health care needs. This study highlights the deficiencies in 
services this population is receiving under one managed Medicaid program. Whereas 
behavioral health services are widely employed, underutilization of medical and 
surgical consults compromises patient awareness of available interventions. Moving 
forward, we believe that a multidisciplinary clinical approach to streamlining patient care 
is necessary. 
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Purpose: Moyamoya angiopathy (MMA) is a very rare cerebrovascular disease 
characterized by bilateral stenosis or occlusion of the distal internal carotid arteries at 
the base of the brain with compensatory collateral vessel formation leading to strokes in 
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childhood and the fourth decade of life. Twelve altered genes that predispose individuals 
to MMA are known, but the majority of cases do not have identified genetic triggers. 
Therefore, we sought to identify them. 
 
Methods: We performed whole exome sequencing of samples from 39 trios (affected 
children and their unaffected parents). Peddy software was used to check the quality of 
the sequencing data and the relationships among the samples. Gemini software was 
used to identify rare (minor allele frequency, ≤0.01% in the control population in the 
gnomAD database) predicted pathogenic (Combined Annotation Dependent Depletion 
score, ≤20) variants following de novo transmission (present in the child, absent in the 
parents). 
 
Results: We identified de novo variants of two known genes—RNF213 (n = 3) and NF1 
(n = 1)—and three novel genes—CHD4 (n = 1), CNOT3 (n = 2), and SETD5 (n = 1). A 
cohort of 158 additional unrelated probands provided further proof that rare pathogenic 
variants of CHD4 (n = 6), CNOT3 (n = 2), and SETD5 (n = 2) predispose individuals to 
MMA. Previous studies identified de novo variants of these genes in children with 
developmental disorders, intellectual disability, and congenital heart disease. Phenotypic 
similarities between our MMA patients harboring de novo variants and those previously 
reported—neurodevelopmental abnormalities and head, eye, ear, nose, and throat 
abnormalities—expand the pleiotropy associated with de novo variants of CHD4, 
CNOT3, and SETD5 to include MMA. 
 
Discussion and Conclusion: These genes encode proteins involved in chromatin 
remodeling and, taken together with previously reported genes leading to MMA-like 
cerebrovascular occlusive disease (YY1AP1 and SMARCAL1), implicate disrupted 
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chromatin remodeling as a molecular pathway predisposing patients to large artery 
occlusive cerebrovascular disease. Furthermore, these data expand the spectrum of 
phenotypic pleiotropy due to genetic alteration of CHD4, CNOT3, and SETD5 beyond 
developmental disorders to later onset disease in the cerebrovascular arteries, thus 
emphasizing the need to assess the clinical complications into adulthood for genes 
associated with developmental disorders. 
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Background: Alcohol consumption, lack of physical activity (PA), and obesity are all 
cancer risk factors that have the potential to co-occur. Although PA and alcohol 
consumption have been positively associated in some racial/ethnic groups, this 
relationship is less studied in Hispanics. Whereas PA has had a consistent inverse 
relationship with obesity, the relationship between alcohol consumption and obesity is 
more nuanced, with current drinkers having lower risk of obesity than never-drinkers. 
The first aim of this study was to assess the relationship between alcohol intake and PA 
in Hispanic adults. The second aim was to assess the independent and interactive 
effects of PA and alcohol consumption on obesity and evaluate how this relationship 
differs according to sex and country of birth. 
 
Methods: Data from the Mano a Mano Cohort of Mexican-origin individuals living in the 
greater Houston area were used. Only individuals recruited into the cohort since 2012 
were included. Trained field staff measured their height and weight. Data were collected 
with interviewer-administered questionnaires, which included self-reported PA, alcohol 
intake (never-drinker, former drinker, or current drinker), and demographic 
characteristics. PA was categorized as high (≥1,500 MET minutes/week), moderate 
(≥600 MET minutes/week), or low (all others). Logistic regression was used to assess 
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the association of PA and alcohol consumption with obesity and body mass index (BMI), 
including an interaction term in the model. 
 
Results: The study participants (n = 3,897) had an average age of 49 years, were 
mostly women, and had not attained a high school degree. Most were obese (60%) and 
never-drinkers (67%). More never-drinkers had low levels of PA (42%) than moderate 
(32%) or high (26%) levels. More current drinkers had high PA levels (32%) than did 
never-drinkers (26%) and former drinkers (24%). Obese individuals did less PA and had 
a greater proportion of never-drinkers when compared with nonobese individuals. A high 
PA level was protective against obesity in the entire sample (adjusted odds ratio [AOR], 
0.81 [95% confidence interval (CI), 0.68-0.95]; p<0.05), female subjects (AOR, 0.73 
[95% CI, 0.60-0.89]; p<0.01), and those born in Mexico (AOR, 0.79 [95% CI, 0.66-0.95]; 
p<0.05). Current drinking was protective against obesity in Mexican-born individuals 
(AOR, 0.77 [95% CI, 0.61-0.97]; p<0.05) and was associated with significantly low BMIs 
in the full sample, male subjects, and Mexican-born individuals. Among never-drinkers, 
compared with those with low PA levels, those with high PA levels were markedly less 
likely to be obese (AOR, 0.79 [95% CI, 0.65-0.96]). The only significant interaction 
between PA and alcohol use was in male never-drinkers: compared with those who had 
low PA levels, those with high PA levels had significantly higher BMIs (beta, 2.67 [95% 
CI, 1.02-4.32]). 
 
Conclusions: In this study of Mexican-origin adults, almost half were obese and never-
drinkers. Both high PA level (vs. low PA level) and current drinking status (vs. never-
drinking) were independently protective against obesity. However, in the full sample and 
most subgroups, never-drinkers with high PA levels (vs. no PA) were the only subjects 
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significantly protected against obesity. These results can inform cancer prevention 
interventions in Mexican-origin adults. 
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The blood-brain barrier (BBB) partitions the circulation from the brain microenvironment. 
The BBB protects the brain from unwanted circulatory substances, supports the unique 
metabolic needs of the brain, and provides a stable environment for brain homeostasis. 
The BBB is also one of the most significant limitations in delivering drugs to treat brain 
pathologies, including neurodegeneration and cancer. Therefore, identifying key pathways 
that can be modulated to allow reliable, effective delivery of drugs to the brain is a critical 
need. The BBB is maintained through complex interactions among cells of the 
neurovascular unit, which comprises endothelial cells (ECs), pericytes, astrocytes, 
microglia, and neurons. These cell-cell interactions precisely control which factors enter 
and exit the brain. Growing evidence demonstrates that astrocytes play crucial roles in 
regulating EC barrier function1-3, making them excellent candidates to study BBB 
modulation. Nevertheless, recent evidence demonstrates that astrocytes display 
functional heterogeneity that may be related to differences in their regional location in the 
brain4,5. Perivascular astrocytes (PAs) are the most abundant astrocyte type in the 
neurovascular unit, where their end feet cover nearly 80% of the cerebral vascular surface 
and perform a wide array of functions. PAs are of particular interest in light of increased 
evidence that disruption of PA-vascular coupling by glioma cells is associated with 
increased tumor invasion4. Despite several studies demonstrating that PAs play important 
roles in maintaining the integrity of the BBB, very little is known about the molecular 
properties of PAs, how PAs and ECs interact to maintain proper BBB functions, or how 
these events are altered in cancer. This is due to a lack of suitable in vivo models that 
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selectively distinguish PAs from other astroglial cell populations. As an important first step 
in deciphering this unique biology, we generated a genetically engineered mouse model 
(Mlc1-EGFP) in which EGFP is selectively expressed in PAs6. Using this novel mouse 
model, we established an efficient protocol to fractionate Mlc1-EGFP+ cells from the 
cortices of adult Mlc1-EGFP mice using fluorescence-activated cell sorting. Further 
marker analysis showed that Mlc1-EGFP+ cells express Mlc1 and other astrocyte 
markers. A purified PA population is suitable for a wide range of molecular and functional 
studies to define specialized properties that regulate BBB function and homeostasis. 
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Objectives: Anaplastic lymphoma kinase (ALK), an oncogenic receptor tyrosine kinase, 
has emerged as a therapeutic target in various cancers, especially non-small cell lung 
cancer.  Although several ALK inhibitors have gained regulatory approval, clinical 
evidence indicates that long term benefit is often limited by the acquisition of resistance 
deriving from secondary point mutations in the target. Importantly, some members of this 
class of compounds are unable to cross the blood-brain barrier, preventing efficacy in 
brain metastases. Herein, we report the fluoroethyl analogues of Crizotinib, Alectinib and 
Ceritinib as potential drug candidates with improved brain penetration.  
Methods: The fluoroethyl analogues of Crizotinib, Alectinib and Ceritinib were 
synthesized using fluoroethyl tosylate coupled with Crizotinib, Alectinib, Ceritinib, 
respectively. In cellulo cytotoxicity screening was performed in ALK-positive lung cancer 
H2228 cells and ALK-negative lung cancer H441 cells. The F-18-fluoroethyl analogues 
of Crizotinib (18F-FECrizotinib), Ceritinib (18F-FECeritinib) were synthesized using 
[18F]fluoroethyl tosylate coupled with Crizotinib, Ceritinib, respectively. [18F]-FEAlectinib 
was synthesized from mesylate or tosylate precursors by direct fluorination with 18F-
fluoride. To study the fluoroethyl ALK inhibitors pharmacokinetics in vivo, positron 
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emission tomography (PET) imaging was performed using the respective F-18 
radiolabeled analogues in healthy nude mice.  
Results: Cytotoxicity of fluoroethyl analogues in ALK-positive H2228 cells showed up to 
nanomolar potency, with no significant change compared to parent compounds. The F-
18-fluoroethyl analogues of ALK inhibitors were obtained with good yields, high purity 
and high specific activity. PET imaging in healthy mice showed significant early brain 
uptake (%ID/cc) for the series as a whole (18F-FECrizotinib %ID/cc: 6.6±2.6; 18F-
FEAlectinib %ID/cc: 8.1±2.6; 18F-FECeritinib %ID/cc: 6.6±1.8 at 5 minutes post injection) 
suggesting penetration of the blood brain barrier.  
Conclusion: These novel fluoroethyl ALK inhibitor analogues show promise for 
enhanced blood brain barrier penetration and therapeutic potential in the central nervous 
system (CNS). 
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